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 SUMMARY 
 
Osteoarthritis is a degenerative joint disease characterized by progressive erosion 
of the articular cartilage.  It is a debilitating disease that affects millions of people and 
costs billions of dollars in treatment and disability claims.  Current treatment involves 
drug therapy to manage pain, reparative surgeries and eventually total joint replacement.  
The ultimate goal is to develop an in vitro tissue engineered cartilage graft or in vivo 
tissue regeneration protocol to heal the arthritic lesion before total joint arthroplasty is 
needed.  However, the development of such therapies has proven to be difficult due to the 
complex biology of the chondrocyte.  Epidemiological studies have established a 
relationship between osteoarthritis and menopause suggesting that estrogen may be 
important in the development of cartilage therapies.  The overall goal of this research 
project was to advance the field of cartilage tissue regeneration by investigating the role 
of 17β-estradiol (E2), an active estrogen metabolite, on the chondrocyte phenotype.  The 
central hypothesis was that E2 would play an important and sex-specific role in regulating 
chondrogenesis. 
The central hypothesis was first tested by investigating the effects of E2 on in 
vitro cultured human articular chondrocytes (HACs).  The higher incidence of 
osteoarthritis in women suggests that there may be intrinsic sex-specific difference 
between male and female articular chondrocytes.  E2 has previously been shown to 
regulate rat growth plate chondrocytes through traditional nuclear receptor mechanisms, 
but only female cells exhibit rapid membrane-associated effects mediated through protein 
kinase C (PKC) alpha.  HACs were obtained at the time of autopsy from three male and 
 
 
xvii
three female donors between 16 and 39 years of age.  Second passage cultures were 
treated with E2 for 24 hours to assess the effects of the hormone on proliferation, matrix 
production, and differentiation.  In addition, the chondrocytes were treated for 3, 9, 90 or 
270 minutes and PKC specific activity was determined.  All chondrocytes were positive 
for aggrecan and estrogen receptor alpha mRNAs but were negative for collagen type II 
mRNA indicating the HAC had lost a portion of their chondrocytic phenotype due to 
monolayer culture.  Only cells from female donors responded to E2 as evidenced by an 
increase in DNA synthesis, sulfate incorporation and alkaline phosphatase activity.  E2 
caused a rapid membrane mediated increase in PKC activity in the female cells within 9 
minutes that was maximal at 90 minutes.  Treatment with the PKC inhibitor chelerythrine 
blocked these effects.  These results provide the first definitive evidence that HACs 
exhibit an intrinsic sex-specific response to E2 and suggest that sexual dimorphism may 
be an important variable for cartilage regeneration. 
The next aim was to develop an animal model to examine the in vivo role of E2 in 
skeletal tissue regeneration.  Demineralized bone matrix (DBM) is an osteoinductive 
material that can stimulate cartilage and bone formation.  The osteoinductivity of 
commercial human DBM is tested in male athymic rats and mice, but DBM performance 
in these animals may not reflect performance in female animals, or provide information 
on E2’s role in the process.  To gain insight, human DBM was implanted bilaterally in the 
gastrocnemius of twenty-four athymic female mice and twenty-four athymic female rats.  
Eight animals in each group were sham-operated (SHAM), ovariectomized (OVX), or 
ovariectomized with E2-replacement (OVX+E2) via subcutaneous slow release capsules.  
Four animals from each group were euthanized at 35 days and four at 56 days.  Uterine 
 
 
xviii
weight and blood estrogen levels confirmed ovariectomy and E2-replacement were 
successful.  Histological sections of implanted tissues were evaluated qualitatively for 
absence or presence of DBM, ossicle formation and new bone or cartilage using a 
previously developed qualitative scoring system (QS).  Histomorphometry was also used 
to obtain a quantitative assessment of the osteoinduction.  OVX mice had a small but 
significant QS decrease at 35 days compared to SHAM mice, confirmed by quantitative 
measurement of ossicle, marrow space, and new bone areas.  The QS in rats was not 
affected by OVX but histomorphometry showed decreased new bone in OVX rats, which 
was restored by E2.  The QS indicated that the number of new bone sites was not reduced 
by OVX in rats or mice at 56 days, but the relative amount of new bone versus marrow 
space was affected and differed with animal species.  Residual DBM was less in OVX 
animals, indicating that DBM resorption was affected.  Cartilage was present in rats but 
not mice, suggesting that endochondral ossification was slower, and indicating that bone 
graft studies in these species are not necessarily comparable.  These results show the 
importance of E2 in human DBM-induced endochondral osteogenesis. 
We then wanted to test our animal model with a tissue engineered cartilage 
construct to study how E2 could specifically affect in vivo chondrogenesis.  The problem 
was approached by developing and characterizing a method for microencapsulating 
growth plate chondrocytes in alginate using high electrostatic potentials.  Hydrogel 
encapsulation has been shown to redifferentiate in vitro expanded chondrocyte and 
stimulate chondrogenesis in mesenchymal stem cells.  Rat costochondral resting zone 
growth plate chondrocytes (RCs) were microencapsulated at low (6x106 cells/ml) and 
high (50x106 cells/ml) cell density, producing microbeads less than 200 micrometers in 
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diameter.  Encapsulated RCs demonstrated minimal proliferation with 98% viability at 
two weeks in low density cultures and 77% viability at high density, indicating potential 
mass transfer limitations.  Gene expression by RT-PCR showed encapsulated RCs 
expressed mRNA for cartilage specific matrix proteins, but light and electron microscopy 
illustrated negligible matrix secretion.  Low and high cell density beads were implanted 
intramuscularly into athymic mice.  Histology of unencapsulated RC controls showed 
cartilage nodule formation.  Low density microbeads implanted for 12 weeks remained 
viable but did not demonstrate chondrogenesis while high density microbeads provided 
evidence of hypertrophic chondrocytes indicating further endochondral differentiation of 
the encapsulated growth plate cells.  This suggests that alginate microencapsulation could 
be restricting growth plate matrix formation but does not block endochondral 
differentiation. 
After establishing a microencapsulation method with RCs, we then wanted to 
apply the technique to HACs and characterize their phenotype.  HACs were 
microencapsulated at low (6x106 cells/ml) and high (50x106 cells/ml) cell density in 
alginate microbeads using the same method developed for RCs.  Encapsulated HACs 
demonstrated minimal proliferation with approximately 90% viability at two weeks for 
both low and high density microbeads, indicating a different response to mass transfer 
limitations compared to RCs.  Light and electron microscopy illustrated metabolically 
active cells with pericellular matrix deposition.  Gene expression by RT-PCR showed 
encapsulated HACs continued to express the cartilage-specific matrix proteins aggrecan 
and COMP during two weeks of in vitro culture, but still did not express collagen type II.  
Encapsulation was shown to increase levels of the transcription factor SOX-9, which is 
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required for chondrogenesis.  The microbeads were then treated with TGF-β1 in an 
attempt to redifferentiate the cells, but the growth factor had no effect on aggrecan, 
collagen type II, or SOX-9 expression.  The development of a tissue engineered construct 
that was capable of forming phenotypical cartilage was not successful with either RCs or 
HACs.  More optimization of the alginate microencapsulation is needed before it can be 
used to test the effects of E2 on in vivo implanted tissue constructs. 
In summary, this work has demonstrated that E2 plays a significant role in 
orthopaedic tissue engineering and regenerative medicine.  We have shown that E2 has an 
important sex-specific function in regulating the phenotype of HACs.  Moreover, the 
osteoinductive properties of DBM are inhibited in an estrogen deficient environment.  
We were unable to produce a tissue engineered cartilage implant to determine what role 
E2 could have on chondrogenesis.  However, our results suggest that the successful 
production of tissue engineered constructs will likely depend on knowing and 
manipulating the actions of sex hormones to ensure chondrocytes in culture form 
physiological cartilage.  Finally, this work shows it is important to take into account the 
type of patient and pathology.  The postmenopausal in vivo environment may be 
inadequate for chondrogenesis and must be considered when designing cartilage grafts. 
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CHAPTER 1 
 
Specific Aims 
 
Millions of people in the U.S. are diagnosed and treated for osteoarthritis each 
year.  It is a debilitating disease that costs billions of dollars in treatment and disability 
claims.  Current treatment involves drug therapy to manage pain, reparative surgeries and 
ultimately total joint replacement.  Attempts to repair the cartilage have variable results 
that are not curative and artificial implants usually fail due to wear and loosening after 
10-20 years.  With the ever increasing longevity in developed nations, a patient may 
require two or three implant revision surgeries over their lifetime.  Unfortunately 
morbidity and mortality increase significantly with each subsequent procedure.  The 
ultimate goal is to develop an in vitro tissue engineered cartilage graft or in vivo tissue 
regeneration protocol to heal the arthritic lesion before total joint arthroplasty is needed.  
However, the development of such therapies has proven to be difficult due to the 
complex biology of the chondrocyte.  Epidemiological studies have established a 
relationship between osteoarthritis and menopause suggesting that estrogen may be 
important in the development of cartilage therapies. 
The overall goal of this research project was to advance the field of cartilage 
tissue regeneration by investigating the role of 17β-estradiol (E2), an active estrogen 
metabolite, on the phenotype of chondrocytes. Specific Aim 1 focused on establishing 
and characterizing a primary human articular chondrocyte (HAC) cell source, and then 
examining the response of the chondrocytes in culture to E2.  Specific Aim 2 involved 
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establishing an ovariectomized animal model to investigate the effects of E2 on in vivo 
orthopaedic tissue implants.  Specific Aim 3 entailed developing and characterizing a 
microencapsulation method for in vitro culture and in vivo delivery of chondrocytes to 
study the effects of E2 on chondrogenesis.  The central hypothesis was that E2 plays an 
important and sex-specific role in regulating chondrocyte phenotype and chondrogenesis. 
 
SPECIFIC AIM 1: To determine the response of human articular chondrocytes to 17β-
estradiol. 
The effect of E2 on HACs has not been previously studied.  It is known that 
articular chondrocytes from both sexes express the cytoplasmic receptors for E2, but post-
menopausal women have a higher prevalence of osteoarthritis than men of the same age.  
This suggests a sex-specific role for E2 in female chondrocytes that is not found in male 
cells.  The objective of this specific aim was to use the information provided by the rat 
costochondral growth plate chondrocyte (RC) cell model to investigate the sex-specific 
effects of E2 on HACs in culture.  The phenotype of the HAC cell source was 
characterized by gene expression and the effects of E2 on proliferation, differentiation 
and matrix synthesis were examined.  A possible E2 signaling mechanism was 
determined by using various cellular signaling activators and inhibitors.  The working 
hypothesize was that E2 would cause a sex-specific response in female chondrocytes 
mediated through a rapid increase in protein kinase C (PKC) activity  that promoted a 
more differentiated state. 
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SPECIFIC AIM 2:  To develop an in vivo model for investigating the effects of 17β-
estradiol on orthopaedic tissue implants. 
The in vivo hormone environment is essential to the physiologic function of 
orthopaedic tissues and is therefore important for any tissue engineered implant.  
Demineralized bone matrix (DBM) is an osteoinductive material that has been shown to 
form bone and cartilage when implanted in mesenchymal tissues that would otherwise 
not form skeletal tissues.  The objective of this specific aim was to use ovariectomy to 
simulate a post-menopausal environment in athymic rodents and analyze the effects of E2 
deficiency on DBM induced endochondral ossification.  The success of the ovariectomy 
was analyzed by measuring serum estrogen levels and uteri weight.  Histomorphometric 
analysis was used to quantify the effects of ovariectomy on skeletal tissue formation.  
The working hypothesize was that in vivo estrogen deficiency would impair DBM 
induced cartilage and bone formation, indicating an important role for estrogen status in 
orthopaedic regenerative medicine. 
 
SPECIFIC AIM 3:  To develop, optimize and characterize an in vivo cell delivery 
system for the investigation of 17β-estradiol on cartilage implants. 
Monolayer culture results in changes in mechanical stresses on articular 
chondrocytes and causes their dedifferentiation towards a fibroblast-like phenotype.  
Encapsulation in alginate has been shown to reverse this process and promote expression 
of chondrocytic phenotype.  The objective of this specific aim was to develop a method to 
microencapsulate chondrocytes in alginate and optimize the system to maximize cell 
viability and chondrocytic phenotype.  The effects of E2 could then be investigated by 
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implanting the alginate microbeads into the animal model developed in Specific Aim 2.  
The working hypothesis was that three-dimensional encapsulation would promote a 
chondrocytic phenotype and redifferentiated chondrocytes. 
 
SIGNIFICANCE 
The current biochemical knowledge of articular chondrocytes, especially in 
humans, has so far been inadequate for the development of cartilage regeneration 
therapies.  Understanding the basic mechanisms of hormone regulation in articular 
cartilage will assist the development of novel therapies for the osteoarthritis and other 
orthopaedic diseases.  The successful production of a tissue engineered cartilage 
replacement will also depend on knowing and manipulating the actions of hormones to 
ensure chondrocytes in culture form physiological cartilage.  The ability to produce a 
tissue engineered cartilage replacement will not be possible until we determine how all 
the independent variables function together to produce cartilage.  It is also important to 
take into account the type of patient and pathology.  The postmenopausal in vivo 
environment may be inadequate for chondrogenesis and must be considered when 
designing cartilage grafts.  The correct chemical mediators are essential for cartilage 
homeostasis and may need to be supplemented even after implantation of the graft to 
ensure continued success.  This study directly addressed these challenges by uncovering 
the basic biology of the human articular chondrocyte and applying this knowledge to 
improve cartilage regeneration strategies. 
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CHAPTER 2 
 
Background and Literature Review 
 
CARTILAGE, CHONDROGENESIS, AND DEGENERATIVE JOINT DISEASE 
Cartilage is a connective tissue of predominantly mesodermal origin that provides 
mechanical support and structural form to many areas of the musculoskeletal system.  
Cartilage differs from most other tissues due to the fact it does not contain vascular, 
nervous or lymphatic structures.  It is composed of a single cell type referred to as the 
chondrocyte and a complex extracellular matrix consisting mostly of collagen and 
proteoglycans. 
Within the developing embryo, chondrogenic cells arise mostly from the 
mesoderm with some structures of the face and neck being neural crest in origin 1.  
Interaction between the mesenchyme and epithelial layers via reciprocal induction, as 
well as cell-cell and cell-matrix interactions, leads to cell condensations and 
differentiation of mesenchymal stem cells into chondroblasts and osteoblasts (bone 
forming cells).  Chondrogenesis is marked by the expression of several cartilage-specific 
molecules, the most important being the transcription factor SOX-9 activated via the Wnt, 
sonic hedgehog (Shh), and indian hedgehog (Ihh) signaling pathways 2-4.  The COL2A1 
promoter region is activated when SOX-9 is bound resulting in up-regulation of collagen 
type II, a cartilage-specific matrix protein.  Synthesis of aggrecan, a cartilage-specific 
proteoglycan, and other collagens like type IX and type XI are also increased in the 
presence of SOX-9.  Other important molecules involved in chondrogenesis include the 
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TGF-β family, bone morphogenetic proteins, fibroblast growth factors, and insulin-like 
growth factors. 
Chondrocytes are round in morphology and vary greatly in size based on the type 
of cartilage, zone, and state of differentiation 4, 5. In general, they range from 10-20 
micrometers in diameter with a single round nucleus.  The chondrocytes represent 5-10% 
of the total cartilage tissue volume but are solely responsible for production and 
maintenance of the extracellular matrix.  A well developed Golgi apparatus reflects this 
primary role.  Chondrocytes respond to an array of chemical mediators including 
hormones, growth factors and cytokines, as well as mechanical and possibly electrical 
stimuli. 
The extracellular matrix of cartilage is composed mainly of water (60-87%), 
collagens (10-30%), and proteoglycans (3-10%) 6.  The matrix can be categorized into 
three distinct regions: the pericellular, territorial, and interterritorial regions 4, 5, 7.  Each 
region has a different composition of collagens, proteoglycans and other matrix 
components.  The pericellular region completely surrounds the chondrocyte forming a 
lacuna and is primarily defined by the presence of collagen type VI 8.  It is rich in 
proteoglycans and noncollagenous protein like fibronectin and is thought to function as a 
transducer of biochemical and biomechanical signals between the chondrocytes and 
extracellular matrix.  The territorial region encompasses the pericellular matrix and is 
composed of a thin collagen fiber network that is theorized to provide extra structural 
protection for the chondrocytes from mechanical deformation.  The interterritorial region 
is the largest component of the cartilage matrix and consists of all the secreted material 
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between the territorial matrices.  It contains most of the proteoglycans as well as large 
covalently linked collagen complexes. 
Collagen complexes form a type of endoskeleton or scaffold that provides 
cartilage with tensile strength 5, 7.  There are at least 15 distinct collagen types found 
within cartilage that contribute to over 50% of the dry weight of the tissue.  All collagens 
are composed of a characteristic triple-helix structure that makes up a majority of the 
molecule’s length.    The major cartilage collagen is collagen type II, which accounts for 
90-95% of the total in most cartilage tissues.  Other collagens found in cartilage include 
types I, IV, V, VI, IX, X and XI.  The large collagen complexes found in the cartilage 
matrix are mostly composed of covalently linked collagen types II, IX and XI.  Collagen 
fibers also act to anchor and immobilize proteoglycans in the cartilage matrix. 
Proteoglycans are complex macromolecules that allow cartilage to resist 
compressive loads 4, 5.  They consist of a protein core with covalently bound 
glycosaminoglycans.  These repeating disaccharide chains are heavily sulfated and 
become ionized at physiologic pH producing a negatively charged matrix that is capable 
of attracting and holding a significant quantity of water.  This osmotic resistance provides 
the support needed to oppose compression.  The major glycosaminoglycans found in 
cartilage are chondroitin sulfate, keratan sulfate and dermatan sulfate.  The largest and 
most abundant core protein isoform in cartilage is called aggrecan.  Several other smaller 
proteoglycans with different core proteins are also found in cartilage including biglycan 
and decorin.  The core proteins of the proteoglycan are then bound to a hyaluronic acid 
backbone via link proteins.  Hyaluronic acid is a glycosaminoglycans but it is not 
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sulfated.  The hyaluronic acid is subsequently linked to the collagen scaffold, anchoring 
the proteoglycans in the extracellular matrix. 
There are also other extracellular matrix components found in minor amounts 
within cartilage 5.  Cartilage oligomeric matrix protein (COMP) is found mostly in the 
pericellular and territorial regions and thought to be involved in cartilage differentiation 
and pathogenesis 9, 10.  Other noncollagenous matrix molecules are also found in small 
amounts including fibronectin, thrombospondin, and tenascin. 
There are three types of cartilage tissue: hyaline, fibrous, and elastic 11.  Hyaline 
cartilage is mostly found in the synovial joints to reduce friction as well as to cushion and 
absorb stress.  Articular cartilage can be divided into four zones: superficial, transitional, 
deep, and calcified 5, 7, 12.  The superficial or tangential zone forms the articulating contact 
surface.  It has a greater density of cells compared to the other zones which are elongated 
parallel to the surface.  The matrix contains the highest concentration of water but with 
decreased proteoglycan content, and the collagen fiber network is aligned parallel to the 
surface similar to the chondrocytes.   The transitional or middle zone has a greater 
concentration of proteoglycans compared to the superficial zone.  In addition, the 
chondrocytes are more spherical with an increased density of synthetic organelles 
indicating a greater role in matrix production.  The collagen endoskeleton has no 
particular alignment as it transitions between the superficial to deep zones.  The 
chondrocytes in the deep zone tend to align in perpendicular columns.  The deep zone has 
the lowest water concentration and greatest concentration of matrix molecules which 
align perpendicular to the surface.  The calcified zone marks the transition from cartilage 
to subchondral bone and is characterized by the presence of collagen type X.  The 
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chondrocytes appear smaller with decreased presence of synthetic organelles.  Certain 
structural components of the thorax, head and neck are also formed of hyaline cartilage 
including the costae, trachea, larynx and the end of the nose. 
The epiphysial or growth plates of the long bones consist of a special type of 
hyaline cartilage involved in endochondral ossification.  Chondrocytes of the growth 
plate are separated into specific zones corresponding to their phenotype and level of 
differentiation 13.  The resting or reserve zone consists of typical hyaline cartilage with 
small chondrocytes and nominal mitotic activity.  The chondrocytes differentiate in 
response to the appropriate biological signals and enter the growth zone which consists of 
a proliferative and hypertrophic zone.  The cells of the proliferating zone undergo many 
successive mitotic divisions and align in long columns surrounded by a proteoglycan rich 
matrix.  The chondrocytes stop dividing and begin to increase in size.  This hypertrophic 
zone is characterized by the expression of collagen type X 7.  Finally, the zone of 
calcification designates the area where the cartilaginous matrix begins to calcify and the 
chondrocytes undergo apoptosis to make way for osteogenic cells. 
Fibrous cartilage is found in areas subjected to higher stress compared to hyaline 
cartilage 11, 13.  Meniscal tissue and the intervertebral discs are examples of fibrous 
cartilage.  These structures contain more collagen type I than hyaline cartilage giving 
them mechanical properties more akin to ligaments and tendons.  Elastic cartilage has a 
matrix high in elastin molecules 11, 13.  This allows the tissue to deform and return to its 
original shape.  Examples include the auricular cartilage around the ear, the epiglottis and 
the eustachian tubes that connect the inner ear to the sinuses. 
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Osteoarthritis is a degenerative joint disease characterized by biochemical and 
molecular changes within the tissue that result in progressive erosion of the articular 
cartilage 14.  For more than 90% of the cases there is no apparent etiology or initial cause 
for the disease and there appears to be a direct relationship to aging.  This form of the 
disease is known as primary osteoarthritis.  When the disease occurs in younger patients 
with a specific cause like traumatic injury or systemic metabolic disorders like obesity, 
then it is referred to as secondary osteoarthritis.  Approximately 80% to 90% of the 
population is afflicted with degenerative joint disease by the age of 65.  Age-dependent 
changes in extracellular matrix components result in decreased mechanical strength and 
resiliency of the cartilage tissue.  Although the relationship to age and traumatic injury 
has often led to the oversimplification of the disease as a function of “wear and tear”, 
research has shown there to be a complex cellular pathogenesis.  Chondrocytes in 
osteoarthritic cartilage produce several cytokines including IL-1 and TNF-α that inhibit 
the production of extracellular matrix while also stimulating the release of 
metalloproteinases that degrade the matrix.  These cytokines are also pro-inflammatory 
which causes an influx of inflammatory cells into osteoarthritic joints.  It is still unknown 
what causes the chondrocytes to release the cytokines and trigger the degradation and 
inflammatory cascade. 
There are numerous surgical procedures aimed at repairing or regenerating 
osteoarthritic lesions 15, 16.  The most common procedure for small defects is a 
microfracture technique that drills into the subchondral bone to elicit bleeding that brings 
progenitor cells and regenerative factors to the lesion.  However, the tissue formed is a 
scar-like fibrocartilage that is mechanically inadequate and usually results in the lesions 
 
 
11
reappearing.  Autologous periosteal and perichondrial grafting has also been used to 
provide progenitor cells to the lesion site.  These methods are limited by the size of graft 
that can be obtained while limiting donor site morbidity, but were capable of forming 
cartilage like tissue in small lesions.   Nevertheless, the grafts eventually fail in most 
cases due to poor integration of the new tissue with the surrounding cartilage and 
subchondral bone leading to delamination and dislodging of the tissue. 
Osteochondral transplantation, or mosaicplasty, has been used to repair large 
cartilage defects 15.  Plugs of healthy cartilage with subchondral bone are harvested from 
the joints of either cadavers (allografts) or a non-load bearing area of the patient 
(autograft) and inserted into the arthritic defect.  The implanted hyaline cartilage/bone 
plugs are initially more stable than the fibrocartilage formed by previous methods.  
However, donor site morbidity can be severe with autografts resulting in progressive 
lesions while disease transfer and rejection are constant issues with any allograft. 
Autologous chondrocyte implantation (ACI) involves harvesting a small amount 
of the patient’s articular cartilage, isolating the chondrocytes, expanding the cells a 
hundred fold and them implanting them into the lesion 15, 16.  Although donor site 
morbidity is reduced due to the need for a smaller biopsy, the method is significantly 
more expensive, requiring an extra surgery as well as the costs of the cell culture which 
can take weeks or months.  In addition, chondrocytes undergo a process known as 
“dedifferentiation” when expanded in monolayer resulting in a more fibroblastic-like 
phenotype with a decreased synthesis of collagen type II and increase in collagen type I 
synthesis.  The procedure has been shown to form hyaline-like repair tissue, but adverse 
effects including graft failures occurs in a majority of patients.  Optimization of the ACI 
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procedure as well as longer terms studies are required before the cost-benefit analysis can 
be thoroughly addressed. 
Eventually attempts to repair or regenerate osteoarthritic joints with the above 
procedures are exhausted while the disease continues to progress.  The severe pain and 
morbidity of bone to bone contact can be managed with pain medications for only so long 
before a total joint replacement is required.  The artificial implants are usually made of 
chromium or titanium with polymer pads at the site of articulation and are very successful 
at restoring function to the joint 17.  However, the implants can fail due to wear and 
loosening after 10-20 years depending on the joint and require two or three revision 
surgeries over the lifetime of the patient.  Unfortunately morbidity and mortality increase 
significantly with each subsequent procedure.  The ultimate goal is the development of a 
treatment that can stop the catabolic cytokine cascade and heal the arthritic lesion before 
total joint arthroplasty is needed. 
 
CARTILAGE TISSUE ENGINEERING AND REGENERATIVE MEDICINE 
Injured or destroyed articular cartilage has limited regenerative capability 15.  This 
is due to the low proliferation rate of chondrocytes combined with the avascularity of 
cartilage limiting the flow of progenitor cells and regenerative factors into the site of 
injury.  Moreover, damaged chondrocytes release enzymes called metalloproteinases that 
further degrade the cartilage matrix and propagate the injury.  When the injury is severe 
enough to involve the subchondral bone and result in blood flow to the injured cartilage, 
the repair tissue is a scar-like fibrocartilage that is incapable of handling the compressive 
mechanical loading and eventually deteriorates.  For these reasons and the fact that it is a 
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relatively simple tissue, cartilage has been a major focus of tissue engineering and 
regenerative medicine strategies. 
Tissue engineering refers to the process of creating tissue in vitro for implantation 
into the body.  Regenerative medicine is focused more on how to stimulate in vivo 
regeneration of tissue.  Both these approaches have pros and cons when it comes to 
repairing cartilage injuries 15.  Growth of a tissue implant outside of the body allows 
greater control of the environment.  Measurements of the cartilages characteristics can be 
taken and the parameters tailored for the desired tissue properties.  However, in vitro 
tissue does not benefit from the complex in vivo biochemical and mechanical 
environment, which has so far been impossible to replicate precisely.  Moreover, 
integration of the tissue engineered implants with native tissue has show variable success.  
Attempts to regenerate cartilage in vivo can overcome the issues of integration, but there 
are other problems to be addressed.  Similar to other load bearing tissues like bone and 
muscle, cartilage is constantly under the influence of mechanical forces.  De novo 
cartilage tissue can easily be dislodged or degraded before it has time to fully form and 
integrate.  The in vivo environment can also be hostile to regeneration due to the release 
of pro-inflammatory and pro-degradative molecules and factors like interleukins and 
metalloproteinases.  It is currently unclear which approach is superior, but future 
techniques for cartilage repair will likely utilize aspects of both methods. 
Tissue engineering or regenerative medicine strategies rely on one or a 
combination of three components: cells, scaffolds, and the environment 15, 16.  A range of 
cell sources from differentiated adult cells to totipotent embryonic stem cells have been 
investigated for applications in cartilage repair.  Each cell source has its own advantages 
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and disadvantages.  For example, an autologous differentiated adult chondrocyte cell 
source already expresses the desired cartilage specific cellular processes, but they are 
difficult to harvest in sufficient quantities due to donor site morbidity.  An allogeneic 
chondrocyte source from a cadaver bypasses the problem of donor site morbidity but then 
raises further immunological obstacles.  Moreover, differentiated chondrocytes are 
difficult to expand in monolayer culture due to slow proliferation rates and because they 
undergo a process known as “dedifferentiation” in which they take on a more fibroblastic 
type phenotype with decreased expression of collagen type II and increased expression of 
collagen type I.  Stem cells have the ability to undergo repeated mitotic division without 
altering their phenotype and therefore have been investigated as a solution to the problem 
of in vitro expansion.  Most of the studies with stem cells have focused on adult 
mesenchymal stem cells due to the inherent legal and ethical question surrounding the 
use embryonic stem cells.  Adult mesenchymal stem cells have the benefit of being an 
autologous cell source that can potentially be harvested from a variety of tissues of 
mesodermal origin including bone marrow stroma, muscle, and adipose tissue.  However, 
since they are undifferentiated pluripotent cells they must be stimulated either in vitro or 
in vivo with the appropriate chondrogenic environment to become chondrocytes.  Several 
studies have demonstrated that supplementation with growth factors like TGF-β, BMP, 
and IGF-1 can promote a chondrocytic phenotype, but the stability of the differentiation 
is unknown. 
Artificial scaffolds have been used in tissue engineering to provide a structure on 
which cells are seeded, as well as in regenerative medicine as a way of recruiting cells 
and providing mechanical support to enhance tissue regeneration 15, 16.  Numerous types 
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of synthetic and biological materials have been examined including polymers, hydrogels, 
proteins, and extracted processed tissue.  The ideal material for tissue formation or 
regeneration needs to be biocompatible with respect to the seeded cells or surrounding 
tissue.  In addition, the materials must be bioresorbable and biodegradable to allow their 
eventual replacement with functional tissue.  Porous polymers scaffolds of lactic and 
glycolic acid have been commonly used for cartilage tissue engineering as well as 
purified porous sponges of various collagens.  Hydrogels of gelatin or polysaccharides 
are also popular in cartilage tissue engineering as they more closely mimic the water rich 
matrix of native tissue.  However, hydrogels provide minimal mechanical support once 
implanted and therefore can jeopardize the success of the implant in load bearing 
applications without proper rehabilitation protocols.  Extracted decellularized 
extracellular matrixes from various tissues like bone or intestinal submucosa are rich with 
growth factors and signaling molecules that are capable of recruiting and stimulating 
differentiation of adult stem cells at the site of injury.  These differentiated cells can then 
produce their own matrix and regenerate the tissue.  But similar to hydrogels, the 
decellularized matrix is not mechanically supportive. 
The final component to be considered when designing a tissue repair strategy is 
the environment 16.  This includes biological, chemical, mechanical, and in some cases 
electrical stimulation of the cells, scaffolds, or site of repair.  The addition of growth 
factors to the culture media of in vitro tissue constructs or to the site of intended in vivo 
tissue regeneration can enhance tissue formation.  Moreover, other bioactive molecules 
can inhibit undesired pathological processes like inflammation and scar formation.  Most 
cells require specific matrix interactions for proper phenotypical expression.   Therefore, 
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the addition of tissue specific matrix molecules can be beneficial.  In addition, the body is 
a dynamic environment and most tissues, especially those of the musculoskeletal system, 
are subject to an array of mechanical shears and stresses.  Attempts to mimic these forces 
in vitro have been shown to be advantageous.  The use of magnetic fields to produce 
electric fields as well as the direct application of electric current has also been 
investigated for nervous, muscular, and bone.  Given the myriad of options, the real 
challenge is deciding which environment is required to achieve the desired outcome. 
 
ESTROGEN AND SEXUAL DIMORPHISM IN ORTHOPAEDICS 
Estrogens are steroid hormones most often associated with female development 
and reproduction.  Like all steroid hormones, estrogens are derived from cholesterol and 
contain the characteristic four ring structure 18.  They are directly synthesized from 
androgens via loss of the C-19 methyl group and formation of an aromatic A-ring.  There 
are three estrogens found in normal human physiology: estrone, estriol, and 17β-estradiol 
19.  The most active form is 17β-estradiol (E2) being 12 times more active than estrone 
and 80 times more active than estriol.  The ovaries secrete predominantly E2 and it is the 
most prevalent estrogen found in females. 
Steroid hormones classically exert their effects by binding to intracellular 
receptors found in the cytoplasm of the cell 20.  The lipophilic molecules can easily pass 
through the plasma membrane and form hormone-receptor complexes.  These activated 
complexes then translocate to the nucleus where they bind to DNA and stimulate 
transcription of the appropriate genes.  This process is referred to as a genomic response 
and can take minutes, hours, or even days because of the time required for new protein 
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synthesis.  There have been two cytoplasmic receptors identified for estrogens, estrogen 
receptor α (ERα) and estrogen receptor β (ERβ).  Recently, it has also been demonstrated 
that steroid hormones have membrane bound receptors that initiate a cell response via 
secondary messenger signaling cascades 21.  This membrane response is rapid, occurring 
in seconds to minutes.  It is currently unclear how the genomic and membrane responses 
may interact to dictate the cellular response to the hormone. 
Estrogens have many important roles in both male and female physiology 19.  
They are obviously pivotal in the formation of the female reproductive tract and external 
female genitalia during embryogenesis.  Moreover, the menstrual cycle, pregnancy, and 
lactation are all tightly regulated by a careful balance between estrogens and progestins.  
They have several general metabolic effects in both male and females, although much 
less than that of androgens, which include changes in insulin levels, fat deposition, 
protein anabolism, and electrolyte balance.  One of the most important effects of estrogen 
is on skeletal growth and development.  Estrogens are responsible for the initiation of 
puberty and closure of the growth plate in both males and females 22.  In fact, females and 
males deficient or insensitive to estrogens from mutations in the aromatase enzyme or 
estrogen receptors have been shown to grow significantly taller due to delayed epiphysial 
union 23, 24.  Moreover, there has been significant literature that stresses the importance of 
sex hormones in the pathogenesis of several musculoskeletal diseases including 
osteoporosis and osteoarthritis 25, 26. 
Cecil and Archer were the first to suggest a relationship between estrogen and 
osteoarthritis in 1925 when they described a menopause-associated arthritis 27.  Since 
their observations, epidemiological studies have shown both the prevalence and severity 
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of the disease to be a function of the patient’s genetic sex 28-30.  Men exhibit a higher 
prevalence of osteoarthritis before the age of 50, while women have a higher prevalence 
after the age of 50.  Moreover, postmenopausal women are more likely to have a general 
form of the disease that affects multiple joints with greater severity. 
The presence of receptors for E2 in chondrocytes supports these clinical 
observations that articular cartilage is an estrogen sensitive tissue.  Articular cartilage 
estrogen receptors were first discovered in 1982 using radioactive binding assays in 
rabbits 31 and dogs 32.  The presence of estrogen receptors have since been confirmed in 
human articular cartilage by mRNA expression 33 and in situ hybridization 34, and have 
also been found using in vitro cultures of human articular chondrocytes 34 and rat growth 
plate chondrocytes 35. 
Despite the epidemiologic observations and the establishment of estrogen 
receptors in cartilage, the specific physiologic effects of estrogen on chondrocytes are 
still unknown.  Human clinical studies using hormone replacement therapy (HRT) have 
given varying and often conflicting results 36-38.  There has not been a consistent 
correlation between serum E2 levels and the development or progression of osteoarthritis.  
Animal models have likewise shown differing results depending on the model used.  
Meniscectomy-induced osteoarthritis in rabbits has been shown to worsen with E2 
treatment 39 and improve with addition of an anti-estrogen, tamoxifen 40.  Intra-articular 
injection of E2 into the knee joints of ovariectomized rabbits has also been reported as 
chondrodestructive 41.  However, E2 treatment in ovariectomized sheep 42 and 
cynomolgus monkeys 43 resulted in less severe osteoarthritis compared to controls. 
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The molecular and biochemical mechanisms underlying the effects of estrogen in 
articular cartilage have not been thoroughly studied in any species.  On the other hand, 
the effects of sex hormones on growth plate cartilage have been well characterized in the 
rat costochondral model.  Female chondrocytes from both the resting and growth zone of 
the rat growth plate demonstrated a decrease in proliferation and an increase in alkaline 
phosphatase activity when treated with E2 in monolayer cultures 44.  This indicates that E2 
promotes differentiation of the growth plate chondrocytes towards a mineralizing 
phenotype.  Treatment with E2 also resulted in increased deposition of both collagen and 
proteoglycan. These effects were not seen in male cells or with the inactive isoform 17α-
estradiol. 
Further studies suggest that these sex-specific effects of E2 occur through a rapid 
membrane-associated mechanism (Figure 2.1).  Treatment with E2 resulted in a dose-
dependent and time-dependent elevation of protein kinase C (PKC) 45 activity that was 
mediated through G-proteins and phospholipase C (PLC) 46.  A similar increase in PKC 
activity was observed when E2 was conjugated with bovine serum albumin (BSA) to 
prevent diffusion through the plasma membrane 47, thereby inhibiting interaction with 
cytosolic estrogen receptors and eliminating possible genomic effects.  Tamoxifen has 
also been shown to inhibit E2 activation of PKC in growth plate chondrocytes 48.  
Additional studies indicated that this PKC signaling cascade eventually results in 
phosphorylation of the mitogen-activated protein kinases (MAPKs), ERK 1/2 and p38 49.  
MAPKs are then capable of eliciting genomic responses and altering gene expression. 
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Figure 2.1:  17β-estradiol membrane mediated signaling cascade in growth plate 
chondrocytes 
E2 binds to a membrane receptor (mER) and stimulates phospholipase C (PLC) 
activity.  PLC acts upon phospholipids to release inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG).  IP3 causes Ca2+ release from the rough endoplasmic reticulum 
(rER).  DAG and Ca2+ act together to activate protein kinase C alpha (PKCα), which then 
acts upon mitogen-activated protein kinases (MAPKs) to alter gene expression. 
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HYDROGEL ENCAPSULATION OF CHONDROCYTES 
Articular chondrocytes undergo a process known as dedifferentiation when 
cultured in vitro as monolayers.  The lack of a three-dimensional matrix results in the 
chondrocytes expressing a fibroblast-like phenotype and the subsequent decrease in 
cartilage-specific processes.  Chondrocyte dedifferentiation was first described in 
embryonic chick chondrocytes as changes in collagen synthesis 50 and was more recently 
confirmed to occur rapidly with the first few passages in human articular chondrocytes 51. 
The dedifferentiation process is believed to be the result of actin stress fibers that 
form during attachment and spreading of the cells to a two dimensional surface 52-55.  
Benya and Shaffer were the first to demonstrate that encapsulating chondrocytes in a 
three dimensional matrix to maintain their rounded morphology could reverse the 
dedifferentiation process 56.  They showed rabbit articular chondrocytes regained 
expression of collagen type II and aggrecan when cultured in vitro within agarose gels.  
However, agarose proved to be a non-ideal substrate due to the difficulty extracting the 
cells and extracellular components from the constructs. 
Alginate was first used to encapsulate chondrocytes in 1989 by Guo and 
colleagues 57.  It was chosen as a potential matrix due to its inherent physical and 
chemical properties 58.  Alginates are a family of linear polysaccharides extracted from 
various species of brown seaweed.  They are a block copolymer of β-D-mannuronate and 
α-L-guluronate linked via a 1-4 covalent bond.  The ratio of monomers and the block 
pattern is highly variable and dependent on what species the alginate is isolated from.  
The guluronate residues rapidly cross link in the presence of divalent cations like Ca2+ to 
form a solid gel and entrap the chondrocytes.  A chelating agent like sodium citrate can 
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then be added to break down the alginate matrix and release the cells and extracellular 
components. 
The mechanical and material properties of the alginate gel are directly related to 
the molecular size and guluronate content 58.  Longer blocks of guluronate result in more 
cross-linking and therefore a stiffer gel.  Increased cross-linking also results in a more 
chemically stable gel with longer degradation times due to a higher concentration of 
monovalent cations being required to disrupt the gel.  The average molecular weight of 
the alginate also correlates to degradation rate as additional hydrolysis is needed to break 
the interconnected network. Moreover, alginates rich in guluronate create a larger and 
more defined pore structure and directly effect mass transfer within the gel. 
Alginate encapsulation has been shown by several research groups to effectively 
reestablish a chondrocytic phenotype in a variety of dedifferentiated in vitro 
chondrocytes cultures including bovine 59, 60, rabbit 61, 62, and human 59, 63-65 articular 
chondrocytes.  Three-dimensional encapsulation within alginate has also shown to 
promote chondrogenesis in chick mesenchymal cells 62 and fetal rat nasal fibrocartilage 
66.  The current hypothesis is encapsulation of chondrocytes changes the mechanical 
stresses on the cell to those seen in vivo and promotes the expression of cartilage specific 
matrix molecules. 
Several methods have been developed for seeding cells into alginate matrixes 
including injection molding to form constructs of a specific shape 67 as well as extrusion 
68 or emulsification 69 techniques to form beads or capsules.  The most common method 
used is extrusion which involves extruding an alginate-cell suspension through a needle 
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to form droplets that fall into a gelation solution containing divalent cations.  The 
guluronate residues of the alginate then cross-link to form a solid gel and entrap the cells.   
The bead size is a function of the gravitational and capillary surface forces acting 
upon the extruded droplet 70.  The gravitational force (Fg) acts to pull the droplet away 
from the end of the needle and is given by: 
grFg ρπ3
4 3=  
where r is the radius of the droplet, ρ is the density of the alginate solution, and g is the 
acceleration due to gravity.  The capillary surface force (Fγ) acts to hold the droplet to the 
needle tip and is given by: 
γπ2 irF =γ  
where ri is the inner radius of the needle and γ is the surface tension of the alginate 
solution.  Equating the two forces allows an expression for the bead radius to be solved: 
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which demonstrates bead radius is a function of the needle size, surface tension, density, 
and gravity.  The alginates beads produced by the extrusion method are typically 2-4 mm 
in diameter with needle radius being the dominant factor.  Alginate solutions with 
viscosities capable of a reasonable flow rate are typically only 1%-4% giving them a 
comparable surface tension and density to that of water.  Therefore, these parameters 
cannot typically be adjusted to significantly affect bead size. 
A common problem among larger tissue engineered constructs is the development 
of necrotic cores due to mass transfer limitations 71-73.  Smaller beads could overcome 
this problem and may also allow minimally invasive injectable therapies.  Several 
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methods have been developed to disrupt the capillary surface force and reduce the size of 
the alginate beads.  The most frequent methods used with the extrusion method involve 
mechanical disruption with air flow 74 or the application of an electrostatic potential 70, 75.  
The beads produced with an electrostatic potential are up to one thousand times smaller 
in volume compared to beads produced by gravitational force alone.  Moreover, 
application of electrostatic forces is more effective than mechanical disruption, 
generating beads up to one hundred times smaller in volume. 
The electrostatic force (Fe) acts along with the gravitational force (Fg) to 
counteract the capillary surface force (Fγ) and reduce droplet size 70.  The force exerted 
by the external electric field between the needle and gelation solution is given by: 
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where εo is the permittivity of air, ri is the inner radius of the needle, and H is the distance 
from the needle to the solution.  Once again, an expression for the bead radius can be 
solved by equating the capillary force to the disrupting forces: 
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which demonstrates that bead size under the effect of an applied electrostatic potential is 
a function of the surface tension, density, needle radius, permittivity, voltage, drop 
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height, and gravity.  The voltage and height can be easily adjusted to achieve a wide 
range of bead diameters for the desired application. 
Alginate microencapsulation and environmental factors have the potential to 
interact additively or synergistically to promote tissue formation.  Most groups have 
investigated how alginate encapsulated chondrocytes respond to traditional cartilage 
growth factors like IGF-1 or TGF-β 76.  No research has been done on how sex hormones 
like estrogen may affect alginate encapsulated chondrocytes.  However, one study has 
shown that alginate encapsulation elicited an increase in PKCα activity and that this 
enzyme activity was correlated with increase expression and synthesis of collagen type II 
62.  This is the same PKC isoform activated in rat costochondral growth plate 
chondrocytes when treated with E2 45.  This suggests a potential interaction between E2 
and three-dimensional encapsulation on in vitro chondrocyte cultures (Figure 2.2). 
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Figure 2.2:  Potential interaction between estrogen and three-dimensional 
suspension for maintaining chondrocyte phenotype 
Chondrocytes undergo a process known as dedifferentiation when cultured in 
monolayer.  Three-dimensional suspension in hydrogels can redifferentiate the 
chondrocytes back to a normal phenotype, and is in part regulated by protein kinas C 
alpha (PKCα) activity.  This is the same PKC isoform activated by 17β-estradiol (E2), 
thereby suggesting a possible interaction between the hormone and three-dimensional 
encapsulation. 
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CHAPTER 3 
  
Human Articular Chondrocytes Exhibit Sexual Dimorphism in Their 
Responses to 17β-Estradiol 
 
INTRODUCTION 
Epidemiological studies show sex-specific differences in both prevalence and 
severity of osteoarthritis 27-30.  Men exhibit higher prevalence of osteoarthritis before age 
50, while women have a higher prevalence after age 50.  In addition, postmenopausal 
women are more likely to have a general form of the disease that affects multiple joints 
with greater severity.  This epidemiologic and pathologic gap between the sexes 
continues to increase with advancing age.  Attempts to correlate biomechanical 
differences between males and females with the incidence and prevalence of 
osteoarthritis have failed to identify a causative factor, suggesting that there may be 
innate differences at the cellular level that contribute to disease severity. 
One possibility is that sensitivity to estrogen plays a role.  The presence of 
estrogen receptors (ER) alpha and beta in chondrocytes supports clinical observations 
that articular cartilage is an estrogen-sensitive tissue 31-34.  The parameters by which 
estrogen modulates chondrocyte behavior are not well understood, however.  Human 
clinical studies using hormone replacement therapy have failed to show a consistent 
correlation between serum estrogen levels and development or progression of 
osteoarthritis 36-38.  Animal models have likewise shown differing results depending on 
the model 39-43. 
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Studies examining effects of the active estrogen metabolite, 17β-estradiol (E2), on 
growth plates of mice and rats in organ culture indicate that responses to the hormone 
differ in a sex-dependent manner 77, suggesting that the sexual dimorphism is at the 
cellular level.  ERα and ERβ are present in rat growth plate chondrocytes (RGPC) 48, but 
female cells possess more high affinity receptors than male cells 35.  In addition, there are 
marked differences in physiological responses of male and female RGPC cells to E2 44.  
Female cells demonstrated decreased proliferation and increased alkaline phosphatase 
activity, indicating that E2 promotes differentiation.  E2 also affected extracellular matrix 
production, resulting in increased synthesis of both collagen and proteoglycan.  These 
effects were not seen in male cells or with 17α-estradiol. 
Stereospecificity of the response to estrogen suggests a receptor-mediated 
mechanism.  E2 treatment increases membrane fluidity and phospholipid metabolism in 
female cells 78, and also results in rapid elevation of protein kinase C (PKC) activity 45.  
The increase in PKC is mediated through G-proteins and phospholipase C (PLC) 46.  A 
similar increase in PKC activity was observed when E2 was conjugated with bovine 
serum albumin (E2-BSA) to prevent diffusion through the plasma membrane 47, thereby 
inhibiting interaction with cytosolic ERs.  Whereas tamoxifen blocks E2 activation of 
PKC in RGPC cells, neither the ER agonist diethylstilbestrol nor the ER antagonist ICI 
182780 has an effect 48, suggesting that E2 regulates chondrocytes through mechanisms 
other than those traditionally associated with nuclear receptors.  E2 also activates PKC in 
human colon cancer cells from females only 79, and activates PKC in female rat distal 
colon by an ICI 182780-insensitive mechanism 80. 
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Our goal was to determine if sexual dimorphism in response to estrogen is a 
feature of human articular chondrocytes (HAC).  Cells from multiple donors were 
examined to verify that differences in response were due to genetic sex and not normal 
human variation.  We first characterized the HAC to ensure they were phenotypically 
chondrocytes, and then examined their response to E2 by measuring changes in 
proliferation, differentiation and matrix deposition.  Finally, we investigated the potential 
role of PKC signaling in E2 stimulation of HAC. 
 
MATERIALS AND METHODS 
Human Articular Chondrocyte Isolation and Cell Culture 
Articular cartilage was isolated from the femoral condyles and tibial plateaus of 
human donors made available due to autopsy.  Donors had no known history of joint 
disease and histological analysis was performed at the time of isolation to confirm the 
absence of any pathologies.  The articular cartilage was cut into small pieces and washed 
twice for 20 minutes with Hanks’ balanced salt solution (HBSS) containing 1% penicillin 
and streptomycin.  The washed cartilage was digested for 1 hour with 0.25% trypsin-1 
mM ethylene diamine tetraacetic acid (EDTA), followed by treatment with 0.2% 
collagenase for 3 hours.  All enzymes were prepared in HBSS.  The digested suspension 
was passed though a 40 μm mesh sieve and centrifuged at 2000 rpm for 10 minutes.  The 
supernatant was removed and the chondrocytes were resuspended in full media 
containing 88% Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin, and 1% L-ascorbic acid 81. 
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Isolated primary HAC were plated on T75 flasks, grown to confluence, and 
harvested using 0.25% trypsin-1 mM EDTA.  The cell suspension was centrifuged at 
2000 rpm for 10 minutes, the supernatant removed, and the cells resuspended in cold 
DMEM, 20% FBS, 1% penicillin/streptomycin, and 5% dimethyl sulfoxide (DMSO).  
The chondrocytes were then frozen at –80oC and shipped overnight from La Jolla, CA to 
Atlanta, GA.  The chondrocytes were thawed, centrifuged, resuspended in full media and 
plated on T75 flasks.  These cultures were grown to confluence and passaged one time as 
above.  Thus second passage HAC cells were used for all experiments.  Confluent second 
passage cultures were also used to assess expression of chondrocyte phenotypic markers.  
It was necessary to expand the cells in culture in order to obtain sufficient numbers for 
each set of assays. 
Characterization of Cell Source 
Articular chondrocytes dedifferentiate when expanded in monolayer cell culture 
56, 82.  Therefore, reverse transcription polymerase chain reaction (RT-PCR) was used to 
assess the phenotype of the second passage HAC by measuring the mRNA expression of 
aggrecan, collagen type I, collagen type II, and collagen type X.  Total RNA was 
extracted from the chondrocyte cultures with Trizol reagent.  Lipophilic contaminants 
were removed by adding chloroform and centrifuging for 25 minutes at 4700 rpm.  The 
aqueous phase was then washed with isopropyl alcohol to precipitate the RNA, and 
centrifuged for 20 minutes at 4700 rpm to form a pellet.  The pellet was washed with cold 
70% ethanol and centrifuged for 15 minutes at 4700 rpm.  The supernatant was removed 
and the pellet allowed to air dry.  The RNA was then dissolved in diethylpyrocarbonate 
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(DEPC) treated water and the purity and quantity was determined by UV 
spectrophotometry. 
The total RNA sample from each donor was reverse transcribed using the First-
strand cDNA Synthesis Kit (Amersham-Biosciences, Piscataway, NJ) and the specific 
anti-sense primer for each mRNA of interest.  The cDNA was amplified using the Fisher 
PCR kit (Fisher Scientific International, Hampton, NH) and the specific sense and anti-
sense primers.  PCR conditions for each cycle included a 30 second denaturation at 94 
oC, a 60 second annealing at 50-65 oC depending on the primer used, and a 30 second 
extension at 72 oC.  The PCR-amplified products were run on 5% polyacrylamide gels 
using a buffer consisting of 0.9 M Trizma® base (tris[hydroxymethyl]aminomethane), 
0.9 M boric acid, and 20 mM EDTA.  Primary human fibroblast RNA was used as the 
positive control for collagen type I, and RNA extracted from rat growth plate cartilage 
was used as the positive control for collagen type X.  The negative control for the 
extracellular matrix components was human lymphocyte RNA.  RT-PCR for ERα was 
performed as above except RNA from human ovarian tissue was used as a positive 
control.  RT-PCR primer information is summarized in Table 3.1. 
Cell Proliferation 
DNA synthesis via [3H]-thymidine incorporation was used to estimate cell 
proliferation in response to E2 83.  Second passage HAC were grown to subconfluence in 
96-well plates, and made quiescent for 48 hours by incubating with media containing 1% 
FBS.  The cells were then treated with 10-11 to 10-7 M E2 in 1% FBS media for 24 hours.  
Four hours prior to harvest, 0.05 μCi of [3H]-thymidine was added to each well, giving a  
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Table 3.1:  RT-PCR Primers for Second Passage Human Articular Chondrocytes 
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final concentration of 0.25 μCi/ml.  At harvest, the cells were washed twice with 200 μl 
phosphate buffered saline (PBS), and then fixed by washing three times in 5% 
trichloracetic acid (TCA).  The samples were then allowed to air dry and 100 μl 1% 
sodium dodecyl sulfate (SDS) was added to each well.  The samples were incubated 
overnight at 4 oC, scraped, transferred to scintillation vials filled with 10 ml of Ready-gel 
(Beckman Coulter, Fullerton, CA) and counted for 1 minute.  Each sample was 
normalized by the total protein content per well, as the assay precludes cell counting or 
measurement of DNA content. 
Alkaline Phosphatase Specific Activity 
Cells from each donor were grown to confluence in 24-well plates and treated 
with 10-11 to 10-7 M E2 24 hours prior to harvest.  At harvest, cells were washed twice 
with 500 μl PBS. An additional 500 μl of PBS was added, and the cell layer was scraped 
and transferred to 12x75mm test tubes. Another 500 μl of PBS was added to the test 
tubes, and samples were centrifuged for 20 minutes at 3200 rpm.  The supernatant was 
decanted, another 500 μl of PBS added, and centrifugation was repeated.  The 
supernatant was decanted again, and the pellet was suspended in 500 μl of a 5% Triton X 
solution.  Samples were subjected to 3 cycles of freeze/thaw treatment in a methanol/dry 
ice bath to break up the cell layer pellet and 50 μl of each sample was aliquoted into a 96-
well plate in duplicate. 
A buffer solution consisting of 2-amino-2-methyl-1-propanol (AMP), p-
nitrophenyl phosphate (pNPP), and MgCl2 was mixed in a 1:1:1 (v/v/v) ratio.  Fifty 
microliters of the buffer solution was added to each well in the 96-well sample plates, and 
the plates were incubated at 37 °C.  Samples were incubated until they were a pale yellow 
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color within the range of the standard curve but not longer than 3 hours 84. After 
removing the plates, 100 μl of NaOH was added to stop the reaction, and the plates were 
read in a Bio-Rad microplate reader (Bio-Rad Laboratories, Hercules, CA) at 405 nm.  
Each sample was normalized by the total protein content per well to determine specific 
activity. 
Proteoglycan Production 
[35S]-Sulfate incorporation was used to measure proteoglycan production 85 in 
response to E2.  HAC were grown to confluence in 24-well plates and treated with 10-11 to 
10-7 M E2 for 24 hours.  Four hours prior to harvest, 5 μCi of [35S]-sulfate was added to 
each sample, giving a final concentration of 9 μCi/ml.  At harvest, cells were washed 
once with PBS, 250 μl of 0.25 M NaOH was added, and the cells were scraped and 
transferred to 12x75mm tubes.  Additional NaOH was added and the cell scraping 
repeated.  Samples were vortexed and 50 μl removed for protein determination.  Two 
hundred and fifty microliters of 0.15 M NaCl was added, and the samples were put in 
approximately 5-cm pieces of prepared 0.25 mm thick, 12-14KD molecular weight cut-
off, dialysis tubing.  The tubing was prepared in a solution of 100 mM NaHCO3 and 10 
mM Na2EDTA.  It was incubated at 60 °C for 2 hours in a shaking water bath.  The 
incubation was repeated for another 2 hours with warm, fresh solution.  The solution was 
replaced with 2 L of warm, ultrapure water, and incubated for 1 hour.  Water replacement 
and incubation were repeated until the water became clear.  The tubing and water were 
cooled to 4 °C and the water was replaced with 10% methanol.  Tubing with the samples 
was placed in a 4 L beaker with dialysis solution (0.15M NaCl, 20mM Na2SO4, 20mM 
Na2PO4, pH 7.4) and incubated at 4 °C for 24 hours.  The solution was replaced every 8 
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hours until the radioactivity was similar to baseline.  Sample tubes were transferred into 
scintillation vials filled with 10ml of Ready-gel and counted for 1 minute.  Each sample 
was normalized by the total protein content per well. 
Protein Kinase C Activity 
HACs from each donor were grown to confluence in 24-well plates and treated 
with 10-11 to 10-7 M of E2 for 3, 9, 90, and 270 minutes.  To isolate the membrane 
response, cells were also treated with 10-11 to 10-7 M E2 conjugated to bovine serum 
albumin (E2-BSA) for 90 minutes.  E2-BSA can not freely pass through the plasma 
membrane and therefore does not bind cytoplasmic receptors.  At harvest, the cells were 
washed twice with 500 μl PBS, and 300 μl of RIPA buffer was added to lyse the cells.  
The PKC activity of each sample was measured using the Biotrak Protein Kinase C 
enzyme Assay Kit and procedure from Amersham Biosciences.  The system is based 
upon the PKC catalyzed transfer of [32P]-PO4 from [32P]-γ-ATP to a peptide specific for 
PKC.  The reaction mixture consisted of 3 mM calcium acetate, 0.075 mg/ml Lα-
phosphatidyl-L-serine, 6 μg/ml phorbol 12-myristate 13-acetate, 150 μM PKC specific 
peptide, and 7.5 mM dithiothreitol in a 50mM Tris/HCl buffer containing 0.05% (w/v) 
azide at pH 7.5.  Twenty-five microliters of the mixture was added to 25 μl of each 
sample.  γ-ATP Phosphorous-32 was mixed with a 1.2 mM ATP, 30 mM Hepes, 72 mM 
magnesium chloride solution at pH 7.4 and a total count of 450,000 ± 20,000 cpm per 5 
μl was obtained.  Five microliters of radioactive ATP buffer was added to each sample.  
The samples were centrifuged and incubated at 37 °C for 15 minutes.  After incubation, 
10 μl of the stop reagent containing 300 mM ortho-phosphoric acid and carmosine red 
was added and the samples were centrifuged again.  The samples were mixed, and 35 μl 
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was transferred to the peptide binding papers provided in the kit.  The papers dried for 5 
minutes and were then washed twice in 75 mM ortho-phosphoric acid solution with 
agitation for 5 minutes.  The paper disks were transferred into scintillation vials filled 
with 10 ml of Ready-gel and counted for 1 minute each.  The total pmols phosphate (P) 
transferred per minute were calculated as follows: P = (T*1000)/(I*R), where I is the 
incubation time.  The specific activity (R) of 1.2 mM Mg [32P]ATP is equal to the total 
count (450,000 ± 20,000 cpm) per 5μl divided by the number of moles of ATP (6x10-9) 
per 5 μl.  The total phosphate (T) transferred to peptides and endogenous proteins is 
equal to the sample cpm minus the blank cpm.  The blank cpm was measured using both 
cell lysate free reactions with reaction buffer to determine the background, and with cell 
lysate containing samples without reaction buffer to measure phosphorylation of 
endogenous proteins.  Both blanks were significantly lower than the samples, but were 
equal to each other, indicating that there was minimal phosphorylation of endogenous 
proteins.  Each sample was then normalized by the total protein content per well. 
Macro Protein Assay 
All samples were normalized by total protein content using the Pierce Macro 
BCA Protein Assay Reagent kit (Pierce Biotechnology, Rockford, IL).  Reagents A and B 
were mixed in a 50:1 ratio to make the working reagent.  Twenty-five microliters of each 
sample was aliquoted in duplicate to 96-well plates, and 200 μl of the working reagent 
was added to the sample plates.  They were incubated at 37 °C for 30 minutes and read in 
the BioRad Microplate reader at 570 nm. 
PKC Inhibition 
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To test whether the effects of E2 on female HAC were mediated by PKC, 
confluent cultures were treated with 10-8 M E2 in the presence and absence of 0.1, 1, or 
10 μM chelerythrine.  Chelerythrine has been shown to specifically inhibit PKC at 
concentrations less than 10 μM in several cell systems 86-88.  We previously showed that 
the effects of E2 on RGPC are blocked by chelerythrine as well as by other PKC 
inhibitors including staurosporine and H-7 89.  Following treatment, [35S]-sulfate 
incorporation was measured as described above. 
 
RESULTS 
Characterization of Phenotype 
Expansion of HAC for two passages in monolayer culture resulted in partial loss 
of phenotypic expression.  The chondrocytes retained their ability to express aggrecan 
core protein mRNA (Figure 3.1), but lost expression of collagen type II mRNA.  The 
cells showed an increase in collagen type I mRNA expression (Figure 3.1), but did not 
show any expression of collagen type X indicating the cells were not differentiating 
towards a hypertrophic phenotype.  Despite loss of collagen type II expression, second 
passage cells were chosen in order to use the same six donors for all experiments, thereby 
reducing potential variability between donors.  The mRNA expression for the above 
matrix components was not dependent on donor sex indicating that loss of collagen type 
II expression was not regulated in a sex-specific manner. 
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Figure 3.1:  Characterization of second passage human articular chondrocytes 
The phenotype of the human chondrocytes (HACs) was assessed by measuring 
the mRNA expression of aggrecan, collagen type I, collagen type II, collagen type X, and 
ERα.  Both female and male cells showed expression of mRNA for aggrecan, collagen 
type I, and ERα.  There was no detectable expression of collagen type II or collagen type 
X.  The results indicate that second passage HACs are partially dedifferentiated towards a 
fibroblastic phenotype.  However, the dedifferentiation is not sex-specific and the 
expression of ERα is retained in both male and female cells as well. 
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Figure 3.2:  Effect of 17β-estradiol on proliferation, differentiation, and matrix 
synthesis 
Second passage human articular chondrocytes (HACs) were cultured in 
monolayers and treated with 10-11 to 10-7 M 17β-estradiol (E2) for 24 hours. (A) [3H]-
Thymidine incorporation was used to measure DNA synthesis.  Female chondrocytes 
showed a significant increase in proliferation compared to control at 10-9 to 10-7 M E2.  
Male chondrocytes did not show a response to E2.  (B) Alkaline phosphatase activity was 
used to indicate changes in chondrocyte differentiation.  Female chondrocytes showed a 
significant increase in alkaline phosphatase activity compared to control at 10-10 to 10-7 M 
E2.  Male chondrocytes did not show a response.  (C) Matrix synthesis was quantified 
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(Figure 3.2 continued) using [35S]-SO4 incorporation to measure proteoglycan 
production.  Female chondrocytes showed a significant response compared to control at 
10-10 to 10-7 M E2.  Male chondrocytes once again did not show a response to E2.  Values 
are the mean ± S.E.M of six cultures from one of two experiments, both showing 
comparable results.  *P < 0.05, treatment vs. control. 
 
 
 
Figure 3.3:  Effect of 17β-estradiol on protein kinase C specific activity 
Second passage human articular chondrocytes (HACs) were cultured in 
monolayers and treated with 10-11 to 10-7 M 17β-estradiol (E2) for 3, 9, 90, or 270 
minutes.  Cells were harvested and protein kinase C (PKC) specific activity was 
measured.  (A)  Female chondrocytes showed a significant response compared to control 
at 10-9 to 10-7 M E2 while male cells did not show a response.  (B) The effect of E2 on 
PKC activity was time dependent for female chondrocytes with a significant response at 
9 min, a maximal response at 90 min, and a return to baseline levels at 270 min.  (C) 
Male chondrocytes did not show a response at any of the time points tested.  Values are 
the mean ± S.E.M of six cultures from one of two experiments, both showing comparable 
results.  *P < 0.05, treatment vs. control. 
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Response to 17β-Estradiol 
HAC exhibited clear sexual dimorphism in their physiological response to E2.  
Chondrocytes from all three female donors showed dose-dependent increases in [3H]- 
thymidine incorporation, significant at 10-9 M E2 (Figure 3.2A).  DNA synthesis in male 
cells did not show any significant response to estrogen at the concentrations used.  E2 also 
regulated chondrocyte differentiation in a sex-specific manner.  Cells from female donors 
showed dose-dependent increases in alkaline phosphatase activity, significant at 10-10 M 
(Figure 3.2B).  Levels of alkaline phosphatase activity in male chondrocytes were 
unchanged by estrogen treatment.  Similarly, E2 treatment caused sex-specific and dose-
dependent increases in [35S]-sulfate incorporation (Figure 3.2C), which were found in 
chondrocytes from all three female donors at 10-10 M.  E2 did not affect this parameter in 
chondrocytes from male donors. 
Both male and female chondrocytes expressed mRNA for ERα (Figure 3.1) and 
there were no apparent differences in mRNA levels due to donor sex.  The presence of 
ERs in both sexes suggests the sex-specific response to E2 acts through a different 
mechanism.  PKC-dependent signaling is clearly involved.  As noted previously for 
female RGPC cells 45 and human colon cancer cells 79, only female human articular 
chondrocytes showed a rapid dose-dependent increase in PKC activity in response to 
estrogen (Figure 3.3).  The effect was significant at 9 minutes, reached a maximum at 90 
minutes, and was found at concentrations as low as 10-10 M E2 for individual patients and 
at 10-9 M E2 when the results for all three patients were combined.  In contrast, 
chondrocytes from male donors did not exhibit a significant response to E2 at any of the  
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Figure 3.4:  Isolation of the rapid membrane mediated response 
Second passage human articular chondrocytes (HACs) were cultured in 
monolayers and treated with 10-11 to 10-7 M 17β-estradiol conjugated with bovine serum 
albumin (E2-BSA) for 90 minutes.  Cells were harvested and protein kinase C (PKC) 
specific activity was measured.  Female chondrocytes showed a significant response 
compared to control at 10-10 to 10-9 M E2.  Values are the mean ± S.E.M of six cultures 
from one of two experiments, both showing comparable results.  *P < 0.05, treatment vs. 
control. 
 
 
 
Figure 3.5:  Effect of protein kinase C inhibition on 17β-estradiol stimulated matrix 
synthesis 
Confluent second passage chondrocytes were treated for 24 h with control media 
or 10-8 M E2 containing 0.1, 1, or 10 μM chelerythrine, a general PKC inhibitor.  (A) 
Chelerythrine inhibited E2 stimulation of PKC activity.  (B) The increase in proteoglycan 
production associated with E2 treatment was completely blocked by the addition of 
chelerythrine.  Values are the mean ± S.E.M of six cultures from one of two experiments, 
both showing comparable results.  #P < 0.05, treatment vs. control.  *P < 0.05, inhibitor 
vs. treatment. 
 
 
43
concentrations or time points tested.  Female HACs also showed a significant increase in 
PKC activity when treated with10-10 M and 10-9 M E2-BSA for 90 minutes (Figure 3.4).  
The large hydrophilic BSA molecules are incapable of passing through the plasma 
membrane, which indicates a rapid membrane-associated response 
Effect of PKC Inhibition 
Treatment of the cells with chelerythrine blocked the stimulatory effect of the 
hormone on PKC (Figure 3.5A) and proteoglycan synthesis (Figure 3.5B).  The effects of 
chelerythrine were dose-dependent.  At the lowest dose (0.1 μM), the inhibitor reduced 
[35S]-sulfate incorporation in E2 treated cultures to control levels, completely abrogating 
the effect of the hormone.  Chelerythrine also appeared to decrease [35S]-sulfate 
incorporation in untreated cultures but this effect was not significant. 
 
DISCUSSION 
It has been difficult to study the effects of hormones on articular chondrocytes in 
vitro because they undergo a process known as dedifferentiation when cultured on two-
dimensional surfaces.  The lack of a three-dimensional matrix causes the down-regulation 
of cartilage specific processes.  Chondrocyte dedifferentiation was first described in 
embryonic chick chondrocytes as changes in collagen synthesis 50, and was later 
confirmed in rabbit and human articular chondrocytes 90. Current biochemical analysis 
has shown that adult rabbit articular chondrocytes have complete loss of collagen type II 
mRNA expression and protein synthesis after two passages when seeded at low densities 
62, defined as 104 cells/cm2.  Experiments on human fetal articular chondrocytes have also 
shown decreased collagen type II mRNA expression in primary cultures after 7-10 days 
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of low density culture 63.  Recently it was shown that dedifferentiation of HAC occurs 
rapidly within the first few passages following primary culture 51.  Our adult HAC model 
had undetectable levels of collagen type II mRNA after two passages, but continued to 
strongly express aggrecan, a chondrocyte-specific proteoglycan core protein.  We were 
unable to verify that the original primary cells produced collagen type II because we used 
banked chondrocytes.  In addition, the first passage cell stocks needed to be subpassaged 
at least once to obtain the number of cells needed for the experiments.  This allowed the 
same six donors to be used for all the experiments, thereby decreasing genetic variability.  
The use of primary cells is preferred, but it is not practical in an adult human articular 
chondrocyte model. 
It is possible that the sex-specific differences we see are due to the 
dedifferentiation effects, but it is unlikely.  The dedifferentiation process does not appear 
to be sex-specific using the standard chondrocytic markers.  However, if monolayer cell 
culture does indeed result in sex-specific changes in the biochemistry of cells then these 
results are even more relevant to the biological research community at large and should 
be further investigated. 
Our results suggest that the sex-specific effects of E2 on proteoglycan production 
are mediated by PKC.  Inhibition of PKC with chelerythrine at concentrations as low as 
0.1 μM completely blocked the stimulatory effects of the hormone.  We previously 
examined the effect of E2 on RGPC with and without chelerythrine and compared 
immunoprecipitation kinase assays using isoform specific antibodies 45.  Chelerythrine 
was shown to specifically inhibit PKCα, which was the isoform shown to be up-regulated 
by E2 in RGPC cells.  We also compared the effects of three PKC-specific inhibitors 
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(chelerythrine, staurosporine, and H7) on TGF-β1 stimulated PKC activity in the same rat 
growth plate model and found similar results with all three inhibitors 89.  Chelerythrine 
has also been used as a PKC-specific inhibitor in other musculoskeletal cell models 91-93.  
However, chelerythrine has been shown to affect other signaling pathways in non-
musculoskeletal cells 94, 95 and has variable effects on PKC in brain tissue 86, 96.  Recently, 
investigators have reported that they failed to observe PKC inhibition when using 
chelerythrine 94, 95, but the assays used in these studies were different from the ones 
reported here and the tissues involved were non-skeletal.  While it is likely that E2 exerts 
its effects via multiple pathways, the results presented here implicate PKC in the 
mechanism. 
The fact that increased PKC activity occurs within minutes suggests that E2 may 
activate a non-genomic signaling pathway through a membrane-associated receptor.  This 
is further supported by the increase in PKC activity observed when E2 was conjugated to 
BSA.  Recent studies have identified both ERα and ERβ in the plasma membrane of 
estrogen-responsive cells 34, 97, as well as the presence of truncated forms of these 
receptors 98.  It is not yet known if one or more of these entities are responsible for PKC 
activation and translocation.  It is possible that male chondrocytes do not express some 
component of this membrane receptor and therefore are not affected by E2.  It is also 
important to note that male chondrocytes are deficient in some part of the genomic 
estrogen signaling pathway since they did not show any response to E2 after 24 hours of 
treatment even though they express ER.  Not all responses to E2 are sex-specific however.  
Both male and female osteoblasts respond to E2 with increased src-dependent MAPK 99.  
Also of note was a shift in the dose response curve of PKC activity in response to E2-
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BSA compared to E2.  This could have been the result of a higher relative concentration 
of E2 at the plasma membrane due to BSA restricting diffusion into the cell.  
In vivo, both male and female chondrocytes produce estrogen via aromatization of 
testosterone 100, but male cells also convert testosterone to 5-hydroxytestosterone (DHT) 
via 5-alpha reductase 101.  Some effects of testosterone are also sex-specific and are 
mediated by DHT 102.  It is unknown what additional effects estrogen metabolites may 
have on male cells. 
Under normal physiological conditions, female cells would be exposed to higher 
levels of estrogen, both systemically as well as locally.  Studies using RGPC cells as the 
model indicate that local levels of estrogen can be as high as 10-8 M 103, which is the 
concentration at with the membrane-associated PKC-dependent signaling is maximally 
stimulated.  These observations support the hypothesis that the female response to 
estrogen involves membrane-associated signaling via PKC in addition to traditional 
nuclear receptor mediated mechanisms, as noted by others for female colon cancer cells 
79 and female rat distal colon 80. The present study is the first to show a clear sex-specific 
effect of the hormone in a normal human cell model. 
Although there are many similarities between the response of RGPC and HAC to 
E2, there are also differences.  Most notably, E2 inhibits DNA synthesis in RGPC 46, 
whereas it stimulates [3H]-thymidine incorporation in human articular chondrocytes.  In 
both instances the effects of the hormone are sex-specific.  Our results indicate that there 
are fundamental differences between human male and female chondrocytes that modulate 
how their response to normal physiological regulators.  This sexual dimorphism has 
important implications for applications that require functional adaptation of donor cells of 
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one sex in hosts of another sex.  Certainly sex is a variable that must be considered in 
interpreting results describing cell behavior in culture and in vivo.  The greater incidence 
in females of osteoarthritis and inflammatory diseases affecting cartilage 27-30 support the 
hypothesis that development of pathology may be due in part to intrinsic sex-specific 
differences in female and male chondrocytes. 
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CHAPTER 4 
 
Osteoinductivity of Demineralized Bone Matrix in 
Immunocompromised Mice and Rats is Decreased by Ovariectomy and 
Restored by Estrogen Replacement 
 
INTRODUCTION 
The high prevalence of osteoporosis and osteoarthritis in post-menopausal women 
creates a demand for autograft in many orthopaedic procedures, including joint 
replacements, spinal fusions, and fracture repair, as well as for increasing bone mass for 
placement of dental implants.  However, the osteopenia present in this patient population 
can make it difficult to obtain sufficient autologous bone graft to meet these clinical 
needs, resulting in the need for allografts and bone graft substitutes 104.  These synthetic 
materials provide osteoconductive surfaces, but they may not be sufficiently osteogenic 
in many applications.  It is often desirable to use an osteogenic material like 
demineralized bone matrix (DBM) to boost the bone forming potential of many bone 
graft substitutes 105, 106. 
DBM has been termed an osteoinductive material based on its ability to induce 
endochondral bone formation when implanted in mesenchymal tissues that would 
otherwise not form bone 107, 108.  Reddi and his colleagues have demonstrated that when 
rat DBM is implanted in subcutaneously in rats, a series of events is initiated that follows 
a well defined time course, beginning with chondrogenesis and resulting in the formation 
of one or more ossicles consisting of a lamellar bone cortex with trabeculae extending 
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into a marrow cavity 109.  The specific components responsible for DBM-induced bone 
formation are not yet fully defined, but there appears to be a correlation between 
osteoinductivity and bone morphogenetic protein content 110.  The response tends to be 
more robust when rodent DBM is used in the same species of rodent, but it is clear that 
the osteoinductive property of DBM is conserved across species, based on studies in 
which the DBM is tested as a xenograft 111-116. 
Commercial preparations of human DBM are assayed for their ability to induce 
bone formation as part of the production process.  Because these are human-derived 
materials, they are tested in immunocompromised mice and rats 117-121.  In this assay, 
DBM granules are placed intramuscularly and then implanted tissue is examined 
histologically for evidence of endochondral ossification.  Depending on the relative 
activity of the DBM preparation, one or more ossicles will form in association with the 
implant.  Using this assay, we and others have shown that human DBM is osteoinductive 
but the degree of osteoinductivity may vary considerably for a number of reasons 
including donor age, as well as DBM processing and sterilization 122-124. 
Host physiology can also affect the osteoinduction response to DBM.  A number 
of studies have shown that aging can negatively impact the ability of DBM to induce 
bone formation 125-129.  Others have shown that treatment with pulsed electromagnetic 
fields can increase the amount of new bone produced in response to DBM 130-132.  Thus, 
both intrinsic and extrinsic factors play a role in the overall outcome.  However, little is 
known about how estrogen deficiency typical of menopause affects induced osteogenesis, 
or if estrogen replacement might modify the effects of estrogen loss. 
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Estrogen is one of the major regulating factors responsible for bone formation and 
maintenance, and the loss of this hormone after menopause often leads to bone loss in 
women 133, 134.  Estrogen may affect osteoinduction in multiple ways.  The hormone has 
direct effects on chondrocytes in the endochondral pathway 46, 47, 49, as well as on 
osteoblasts 135, 136.  Estrogen may also affect remodeling and ultimately resorption of the 
induced ossicles.  It increases production of transforming growth factor beta-1 (TGF-β1) 
by T-cells 137, and reduces production of tumor necrosis factor alpha (TNF-α) 138.  This 
results in a decrease in osteoclast activity 139.  In the absence of estrogen, TNF-α is 
increased and bone resorption is stimulated 140, 141. 
These observations suggest that human DBM-induced bone formation will be 
decreased in the absence of endogenous estrogen and that this reduction can be 
ameliorated by estrogen replacement.  To test this hypothesis, we took advantage of the 
muscle pouch implantation assays typically performed using athymic mice or rats.  In 
general, male animals have been used for osteoinductivity assays for reasons of cost and 
convenience.  It is not known if immunocompromised female animals will respond to 
DBM as has been shown using male animals.  In addition, although both mice and rats 
are used for qualitative scoring of osteoinductivity 119, 142-144, no studies have directly 
investigated whether both animal species respond to commercially available preparations 
of human DBM in a comparable manner using quantitative assessments of the same 
DBM samples. 
The response of athymic mice and rats to ovariectomy adds a further level of 
complexity to the in vivo assay outcomes.  Ovariectomy does not affect bone formation 
or increase bone turnover in athymic mice because these animals lack T-cells 145.  
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Athymic rats also have reduced levels of T-cells, but some T-cells persist 146.  This may 
be the reason why athymic rats, unlike athymic mice, exhibit ovariectomy-induced bone 
loss 147.  The initial event in DBM-induced bone formation at muscle sites is a transient 
inflammatory response that includes monocytes and macrophages 148, but it is not known 
what role these cells play in the osteoinduction process.  The differences in T-cell 
populations in these two animal species suggests that the amount of bone formation may 
vary between the two animal species even in sham operated controls, and further 
differences will result after ovariectomy and estrogen replacement. 
 The overall goal of this study was to determine whether estrogen status affects the 
osteoinductivity of human DBM.  The experiments were designed to test the hypothesis 
that estrogen loss due to ovariectomy results in reduced new bone formation and this can 
be restored by estrogen therapy.  Because human DBM is a xenograft, it was necessary to 
test this hypothesis in an immunocompromised animal model but it was not known 
whether the response of athymic female mice to human DBM would differ from the 
response of athymic female rats.  Accordingly, we examined human DBM 
osteoinductivity in both species. 
 
MATERIALS AND METHODS 
Selection of Host Animals 
Twenty-four inbred albino female Nu/Nu mice (athymic mice) (Harlan, 
Indianapolis, IN) and twenty-four inbred albino female Nu/Nu rats (athymic rats) 
(Taconic, Germantown, NY) were used in this study.  Athymic animals were chosen to 
minimize any immune response to the xenografts, as required by the Institutional Animal 
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Care and Use Committee (IACUC) at the Georgia Institute of Technology.  Moreover, 
athymic animals are typically used by industry to assay osteoinduction ability of 
commercial preparations of human DBM for this reason.  The athymic mice used were 
purchased at 5-6 weeks and acclimatized for three weeks prior to surgery.  The mice 
underwent the surgical procedures when skeletally mature at 8 to 9 weeks of age.  The 
athymic rats were purchased at 11 weeks of age and acclimatized for one week prior to 
surgery.  At 12 weeks of age, when skeletally mature, the rats underwent the surgical 
procedures.  These ages were selected based on information supplied by Harlan and 
Taconic. 
Preparation of DBM Implants 
Human DBM particles, prepared for human clinical use and ranging in size from 
200-500 µm, were obtained as a generous gift from LifeNet, Inc. (Virginia Beach, VA).  
Previously, we used the athymic mouse muscle implantation assay to assess the bone 
induction ability of 27 batches of DBM from LifeNet 143, and from this assortment we 
selected a batch with high osteoinduction activity for the present study.  The DBM 
particles were measured on weighing paper (10 mg for mice and 15 mg for rats) and 
transferred using a metal spatula to #5 gelatin capsules in order to facilitate their 
implantation.  The difference in implant size was not based on animal weight but was 
done to reflect the use of larger DBM implants in rats compared to mice noted in the 
literature 119, 142, 144.  Because the gelatin capsules were not pre-sterilized and the 
weighing and packing of DBM was not performed under clean room conditions, all 
loaded capsules were sterilized by UV light overnight.  We have repeatedly tested control 
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batches of the LifeNet DBM using this method of sterilization and it has been shown to 
not diminish the osteoinductive properties of DBM 119, 143. 
Ovariectomy and Implant Procedures 
All surgical procedures on an animal were performed at the same session under 
isoflurane inhalation anesthesia.  Mice and rats were randomly assigned to one of three 
surgical groups: sham-operated controls (SHAM); ovariectomized (OVX); and 
ovariectomized plus 17β-estradiol (E2) supplementation (OVX+E2).  All animals received 
DBM implants bilaterally in the gastrocnemius muscle of the hind limb as described 
below.  This protocol was approved by the Institutional Animal Care and Use Committee 
at the Georgia Institute of Technology. 
A dorsal approach was used to remove the ovaries as previously described 149.  
For the implantation of DBM, small skin incisions were made over the calf region of each 
hind limb following disinfection, and a pouch was prepared in the muscle by blunt 
dissection 119.  One gelatin capsule was inserted into each pouch and the incision closed 
by clips. 
In those animals receiving estrogen replacement, a slow release device 
(Innovative Research of America, Sarasota, FL) was implanted subcutaneously in the 
nuchal region of the back using the same incision used for the ovariectomy.  A narrow 
path was made by blunt dissection of the subcutaneous tissue from the initial incision to 
the area of implantation.  The slow release device was then inserted into the nuchal 
subcutaneous pocket uses forceps.  The skin over the wound was then closed with clips, 
taking care not to pinch the implant.  Each mouse was implanted with a 60 day release 
pellet containing 10 µg E2 (0.17 μg/day), and each rat received a 60 day release pellet 
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containing 120 µg E2 (2.0 μg/day).  The dosage was based on the minimum dosage 
necessary to restore uterine weight to ovariectomized athymic mice 150, and then scaled 
up for the rats as a function of animal weight. 
Pair Feeding of Animals 
Rats and mice that have been ovariectomized tend to have increased appetites and 
gain weight.  In order to eliminate weight gain as a confounding variable 151, 152, the 
animals in this study were pair fed.  The consumption of food by the ovariectomized 
animals was metered by the intake of the sham-operated controls.  The success of the pair 
feeding regimen was verified by weighing the animals at the time of surgery and then 
weekly thereafter. 
Effectiveness of the Ovariectomy and Estrogen Replacement Regime 
To verify the success of ovariectomy, estrogen levels were measured from blood 
samples collected at the time of euthanasia.  At the ends of the two study periods (35 and 
56 days), the animals were euthanized by thoracotomy under isoflurane anesthesia.  This 
method of euthanasia facilitated the drawing of blood directly from the heart cavity 
sufficient for estrogen analysis.  Estrogen levels in the blood samples were determined 
using an ultra-sensitive estradiol radioimmunoassay (RIA) kit (Diagnostic Systems 
Laboratories, Webster, TX).  In addition, the uteri were removed by sharp dissection and 
weighed. 
Histological Evaluation 
Following euthanasia at 35 or 56 days, the whole of the calf region was excised to 
ensure complete recovery of the implant site and then fixed in 10% neutral buffered 
formalin.  Histological processing was done at North American Science Associates 
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(NAMSA), Inc. (Northwood, OH).  After decalcification in 5% formic acid, tissues were 
embedded in paraffin, sectioned and stained with hematoxylin and eosin.  Three 
consecutive cross-sectional cuts (3-4 µm each) were made at three different levels of the 
limb (9 total sections per leg) to ensure visualization of the implant site. 
One section from each implant was used for all analyses.  To determine which 
section to use, all nine sections from each block were evaluated for the presence or 
absence of DBM particles, new bone and new cartilage, as described previously 119.  
Briefly, the methods used were as follows. To ensure that any ossicles were due to DBM-
induced bone formation and not because of osteoconduction due to approximation of 
DBM particles to host bone, the tibia and fibula were used as landmarks and only those 
sections in which ossicle formation was clearly not associated with either bone were 
considered for further analysis.  From this subset, one section from each implant was 
chosen based on the amount of new bone and/or cartilage.  Because the selected section 
was the one with the greatest amount of new bone and/or cartilage, the results were 
biased positively. 
A qualitative score was used to indicate whether bone or cartilage induction had 
occurred and to provide an assessment of the number of ossicles that had formed.  Each 
section was evaluated by two independent examiners and any differences between the 
examiners were resolved by a third examiner.  Third party arbitration was required for 5 
sections of the 864 sections examined, indicating a high intra-observer correlation.  The 
qualitative scoring system for bone was based on the following parameters.  When DBM 
was present but with no cartilage or bone induction, the value “1” was given.  When an 
ossicle was observed, the score of “2” was given, and when 2 or more ossicles were 
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present, the value was “3”.  In sections with very osteoinductive implants, where 70% or 
more of the slide at 10X magnification was covered with one or more ossicles, a value of 
“4” was ascribed.  Thus a section with a single large ossicle covering 70% or more of the 
field at a magnification of 10X would receive a score of 4, rather than a score of 2.  
While this is not a common finding, we have recorded a score of 4 for implants 
containing BMP-2 153, 154. 
There are no “ossicle equivalents” for cartilage, so the qualitative score for 
cartilage was determined by the number of cartilage sites in the selected section.  When 
DBM was observed but no cartilage was present, a score of “1” was given.  One cartilage 
site was scored “2”, and two or more sites received a score of “3”.  In a section where 
70% or more of the slide at 10X magnification was covered with cartilage, a value of “4” 
was assigned. 
Quantitative measurements were made to provide an assessment of the amount of 
new bone and/or cartilage.  Histomorphometric analyses were performed on the same 
histologic sections using a computerized analysis system (Image-Pro Plus, Media 
Cybernetics, Silver Springs, MD).  Areas of the sections to be measured were captured at 
the appropriate magnification by a video camera.  Calibration was performed according 
to the instructions accompanying the software.  The following were measured using a 
stylus to outline each feature: ossicle area composed of the marrow space and 
surrounding cortex (DBM and new bone), marrow area, new bone area (distinct from 
DBM and limb bones), cartilage area, and the total area of residual DBM particles. 
Statistical Analysis 
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The results of the qualitative and morphometric analyses were calculated as the 
means ± SEM for each variable.  The values for all groups represented findings from 4 
animals, each having two implants, providing a sample size of 8.  Previous studies have 
shown the validity of treating each implant as a unit rather than each animal as a unit (2 
sites/animal) 143.  Statistically significant differences between groups of the same species 
were determined by two-way ANOVA and the use of Bonferroni’s modification of 
Student’s t-test.  For both statistical tests, P values ≤ 0.05 were considered significant.  
Power calculations showed that the power varied between 0.54 and 0.89, depending on 
the parameter being measured.  A quantitative statistical comparison of interspecies 
results was not performed due to differences in the two animal species. 
 
RESULTS 
Evaluation of Pair Feeding, Ovariectomy and Estrogen Replacement 
No animals were excluded from the study on clinical grounds after the study 
began.  All animals healed normally following the surgical procedures and there was no 
evidence of infection. 
OVX and OVX+E2 mice grew at the same rate as the SHAM mice, demonstrating 
the pair-feeding regimen was successful (Figure 4.1A).  However, the OVX mice did 
have a statistically significant decrease in weight at 1 week that was not seen in the 
SHAM or OVX+E2.  OVX rats grew at a slightly greater rate than SHAM rats; however, 
the increase was only statistically significant at 6 weeks (Figure 4.1B). The growth of 
OVX+E2 rats was significantly inhibited from 3 to 6 weeks post-surgery, but eventually 
recovered at 7 weeks to that of the SHAM controls. 
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Figure 4.1:  Analysis of pair feeding regimen 
The success of the pair feeding regimen was verified by weighing the animals at 
the time of surgery and then weekly thereafter.  The consumption of food by the 
ovariectomized (OVX and OVX+E2) animals was metered by the intake of the sham-
operated (SHAM) animals.  (A) Mice; (B) Rats.  Values are means ± SEM for N = 8 mice 
per group through 5 weeks (35 days) and N = 4 mice for weeks 6 to 8 (56 days total).  *P 
< 0.05, SHAM vs. treatment.  ●P< 0.05, OVX vs. OVX+E2. 
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Figure 4.2:  Analysis of ovariectomy effectiveness 
The effectiveness of bilateral ovariectomy (OVX) on athymic mice and rats was 
determined by blood serum estrogen levels and uterine weight at 35 days and 56 days 
post surgery.  Sham-operated animals (SHAM) and ovariectomized animals with 17β-
estradiol supplementation (OVX+E2) were used as controls.  Blood serum estrogen levels 
were determined using a radioimmunoassay kit.  (A) Athymic mice in the SHAM and 
OVX groups showed lower estrogen levels at 56 days than 35 days.  OVX resulted in a 
decrease in serum estrogen at 56 days but not 35 days.  (B) Athymic rats did not show a 
difference in estrogen levels over time and the OVX groups demonstrated a significant 
decrease in estrogen levels at both time points.  (C)  Athymic mice showed a significant 
increase in uterus weight from 35 days to 56 days in all experimental groups.  OVX 
caused a decrease in weight that was partially restored with estrogen.  (D)  Uterus weight 
in the athymic rat was stable over time.  OVX resulted in a significant decrease that was 
restored with estrogen. Values are the mean ± S.E.M of four animals.  *P < 0.05, SHAM 
vs. treatment.  #P < 0.05, 35 days vs. 56 days.  ●P< 0.05, OVX vs. OVX+E2. 
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OVX mice had reduced levels of serum estrogen at 35 days in comparison to 
control animals, but this was not statistically significant and no effect of estrogen 
replacement was evident (Figure 4.2A).  At 56 days, no systemic estrogen could be 
detected in the OVX mice and estrogen treatment restored the hormone to levels 
measured in the sham-operated mice.  In addition, systemic estrogen levels decreased 
with time in the mice.  Ovariectomy of athymic rats reduced serum estrogen levels by 
more than 80% within the first 35 days (Figure 4.2B).  Estrogen replacement restored 
levels of the hormone to those seen in the sham-operated animals.    
Uterine weight doubled between 35 and 56 days in all mouse treatment groups 
(Figure 4.2C).  Uterine weight in the ovariectomized animals was 75% less than in the 
sham operated controls and this difference was maintained over time.  Estrogen treatment 
increased uterine weight by 100% in comparison to the OVX mice that did not receive 
the hormone, but the weight of the uterus was not equivalent to that of sham-operated 
mice, even at 56 days.  Unlike the mice, there was no age-related change in uterine 
weight in the rats (Figure 4.2D).  Uterine weight in the ovariectomized rats was more 
than 50% lower than in sham-operated rats, and treatment with estrogen restored uterine 
weight to that seen in the sham-operated controls.  The changes in uterine weight 
correlated with changes in systemic estrogen.   
Histological Evaluation of Osteoinduction 
All implant sites exhibited DBM at the time of harvest.  Histological evaluation of 
the DBM-implanted tissues demonstrated differences in the response between the two 
animal species (Figure 4.3).  The athymic mouse exhibited the typical structure of large  
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Figure 4.3:  Histological evaluation of DBM induced endochondral ossification 
The effects of estrogen on the osteoinductive properties of human demineralized 
bone matrix (DBM) at 35 days and 56 days were determined using a rodent muscle 
implant model.  Athymic mice and rats were ovariectomized (OVX) and DBM was 
implanted in the hind gastrocnemius muscle.  Sham-operated animals (SHAM) and 
ovariectomized animals with 17β-estradiol supplementation (OVX+E2) were used as 
controls.  The hind limbs were dissected, decalcified, sectioned and stained with 
hematoxylin and eosin.  Images shown are from samples harvested at 56 days.  (A) 
Athymic mice showed large ossicles composed of a marrow cavity (M) surrounded by 
DBM particles (D) and new bone (arrow).  (B, C)  Estrogen levels did not affect the 
general appearance of the ossicles in athymic mice.  Osteoinduction in athymic rats was 
more variable than the mice.  (D)  Cartilage (arrowhead) formation could be seen within 
the DBM without the formation of ossicles.  (G, H)  Large nodules of new bone attached 
to DBM were also noted.  (E, F, I)  When ossicles did form they were usually smaller in 
size compared to the mice and were surrounded by a mixture of cartilage and new bone. 
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Figure 4.4:  Assessment of osteoinduction using a qualitative scoring system 
Osteoinduction in ovariectomized (OVX) athymic mice and rats at 35 days and 56 
days was measured using the following qualitative scoring system.  DBM without bone 
or cartilage was given a value of “1”.  When an ossicle was observed, the score of “2” 
was given, and when 2 or more ossicles were present, the value was “3”.  Implants where 
70% or more of the slide at 10X magnification was covered with ossicles were given a 
value of “4”.  Sham-operated animals (SHAM) and ovariectomized animals with 17β-
estradiol supplementation (OVX+E2) were used as controls.  (A, B) All experimental 
groups for both animal species showed significant osteoinduction.  There was a small 
decrease detected in athymic mice compared to controls in the OVX group at 35 days. 
Values are the mean ± S.E.M of eight implants.  *P < 0.05, SHAM vs. treatment. 
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ossicles filled with bone marrow surrounded by a combination of implanted DBM and 
new bone (Figure 4.3A).  This general appearance was independent of the estrogen status 
of the mouse (Figure 4.3B and 4.3C).  The athymic rat produced much more variable 
results.  In some cases small amounts of new cartilage formed within the DBM particle 
mass without the presence of new bone or a marrow cavity (Figure 4.3D).  In other cases 
large nodules of new bone could be found connected to the DBM particles without the 
formation of an ossicle (Figure 4.3G and 4.3H).  When ossicles did form they were 
smaller compared to the athymic mouse and were usually surrounded by a mixture of 
new bone and cartilage (Figure 4.3E, 4.3F, and 4.3I).  The presence of cartilage or the 
formation of ossicles in the athymic rat did not appear to be correlated with the estrogen 
status of the animal. 
Qualitative assessment of osteoinductivity was similar regarding the two different 
species (Figure 4.4).  The osteoinductivity index was higher in the sham-operated mice 
than in the rats, but in both cases the score was not statistically different from 3.  
Ovariectomy resulted in a small but significant decrease in osteoinductivity at 35 days in 
the mice, but this decrease was no longer evident at 56 days, and estrogen replacement 
prevented the decrease at the early time point (Figure 4.4A).  The qualitative assessment 
of osteoinductivity in the rat indicated that neither ovariectomy nor estrogen treatment 
altered the number of sites of bone formation (Figure 4.4B). 
While the number of bone formation sites was relatively unaffected by 
ovariectomy, ovariectomy did alter the kinetics of bone formation and this was species 
specific (Figure 4.5).  New bone area was significantly lower in OVX mice at both 35  
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Figure 4.5:  Quantitative assessment of osteoinduction using histomorphometry 
Osteoinduction in ovariectomized (OVX) athymic mice and rats at 35 days and 56 
days was measured quantitatively by morphometric analysis of new bone area, ossicle 
area, and bone marrow area.  Sham-operated animals (SHAM) and ovariectomized 
animals with 17β-estradiol supplementation (OVX+E2) were used as controls.  (A)  OVX 
resulted in a decrease in new bone formation in athymic mice and was restored by 
estrogen treatment.  (B)  A similar response was seen in the OVX athymic rats.  (C, D)  
Ossicle area also decreased with OVX in both species, although this was not significant 
at 35 days for the rats.  (E)  Bone marrow area was significantly decreased in the athymic 
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(Figure 4.5 continued) mouse after OVX and was only restored after 56 days of estrogen 
replacement.  (F)  The rats did not show any change in bone marrow area with estrogen 
status.  Values are the mean ± S.E.M of eight implants.  *P < 0.05, SHAM vs. treatment. 
 
 
 
 
 
Figure 4.6:  Analysis of DBM resorption 
Residual DBM area was measured in ovariectomized (OVX) athymic mice and 
rats with muscle implants.  Sham-operated animals (SHAM) and ovariectomized animals 
with 17β-estradiol supplementation (OVX+E2) were used as controls.  (A, B)  Residual 
DBM particles were seen in all implants at both time points.  OVX caused a small 
resorption of DBM in both species.  Values are the mean ± S.E.M of eight implants.  *P < 
0.05, SHAM vs. treatment. 
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and 56 days (Figure 4.5A).  The ossicle size was approximately 50% lower in OVX mice 
at 35 days and this persisted in the OVX animals even though there was a further increase 
in ossicle size in the sham-operated animals (Figure 4.5C).  Estrogen replacement 
resulted in greater ossicle area but there was considerable variability among the mice that 
precluded demonstration of statistical significance.  The marrow space was also less in 
the OVX mice compared to sham-operated animals (Figure 4.5E).  Estrogen did not alter 
this at 35 days, but at 56 days, the size of the marrow cavity within the ossicle was 
comparable to that of sham-operated controls. 
New bone area in the ovariectomized rats was less than 50% of the new bone area 
in sham-operated animals.  Estrogen replacement increased new bone formation but the 
levels achieved were not as great as in the sham-operated rats (Figure 4.5B).  OVX rats 
also had 50% less ossicle area at 35 days, and this effect was maintained at 56 days 
(Figure 4.5D).  Estrogen treatment restored ossicle area to that of sham-operated control 
rats.  Unlike the OVX mice, there was no time-dependent change in the size of the 
marrow cavity in OVX rats (Figure 4.5F).  In addition, ovariectomy and estrogen did not 
significantly affect the marrow area in the athymic rat. 
The amount of residual DBM was similar in both animal species.  Ovariectomized 
mice had a small but statistically significant reduction in the amount of residual DBM 
(Figure 4.6A), as did ovariectomized rats (Figure 4.6B).  Estrogen replacement prevented 
this loss in both species. 
Although DBM acts via endochondral ossification, evidence of cartilage was 
found only in the rat implants.  Ovariectomy had no effect on the number of cartilage 
sites at either time point, whether the animals were treated with estrogen or not (Figure 
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4.7A).  In addition, it was not possible to demonstrate statistically significant differences 
in new cartilage area due the high variability of the sample population, although the trend 
would suggest ovariectomy in rats may result in increased cartilage formation in response 
to DBM (Figure 4.7B).  Because delayed cartilage formation or chondroclasis had not 
been anticipated, the study was not designed with sufficient power to assess statistically 
significant differences in these parameters. 
 
DISCUSSION 
It is known that estrogen regulates normal bone growth and development; this 
study demonstrated for rats and mice that it also regulates endochondral bone formation 
stimulated by an osteoinductive agent, human DBM.  As noted previously for rat DBM 
implanted in ovariectomized rats 155, the number of sites of human DBM-induced new 
bone formation was not significantly affected by estrogen loss.  However, measurement 
of ossicle area showed that the ossicles in estrogen deficient animals were smaller than in 
sham-operated control animals.  Moreover, the present study demonstrated that this 
reduction in size could be prevented in part by estrogen replacement.  These observations 
indicate that estrogen regulated bone growth and not the initial osteoinduction event per 
se. 
This study is the first to examine the response of athymic mice and rats to the 
same commercial preparation of human DBM.  Athymic mice and rats are frequently 
used to test xenogeneic materials because of their compromised immune systems, but 
they are very different with respect to the nature of their T-cell impairment.  Although the  
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Figure 4.7:  Assessment of DBM induced chondrogenesis 
Cartilage induction in ovariectomized (OVX) athymic rats at 35 days and 56 days 
was measured using the following qualitative scoring system.  When DBM was observed 
but no cartilage was present, a score of “1” was given.  One cartilage site was scored “2”, 
and two or more sites received a score of “3”.  In a section where 70% or more of the 
slide at 10X magnification was covered with cartilage, a value of “4” was assigned.  
Sham-operated rats (SHAM) and ovariectomized rats with 17β-estradiol supplementation 
(OVX+E2) were used as controls.  (A) All experimental groups for both animal species 
showed significant cartilage formation but there was no difference detected due to OVX.  
(B)  Quantitative morphometric analysis of the cartilage area also did not show any 
significant differences between the experimental groups. Values are the mean ± S.E.M of 
eight implants. 
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difference in DBM dose and body size precludes a direct comparison between these two 
inbred animal species, the results show that human DBM is capable of initiating new 
bone formation in ectopic muscles sites of both species, but the nature of the response 
appears to be species dependent.  We observed classic ossicles in the mouse, 
characterized by a well defined marrow space surrounded by cortical bone.  In contrast, 
bone induction in the rat was characterized by new bone linking adjacent DBM particles, 
and only infrequently were well defined ossicles present. 
Differences were also noted with respect to the rate of osteoinduction.  Ossicle 
size increased in the mouse with time in all treatment groups, suggesting the possibility 
that osteoinduction may have been influenced by factors associated with normal animal 
growth, even after skeletal maturity.  Given that no cartilage was evident in the mouse 
ossicles, we have concluded that the increase was due to direct apposition of bone.  In 
contrast, rat ossicle size did not change with time, although the rats increased in weight.  
Moreover, even at 56 days post-implantation, DBM-induced cartilage persisted in the 
OVX rats, suggesting that endochondral ossification was at a slower rate.  Estrogen 
stimulates the differentiation of growth plate chondrocytes in vitro and in vivo 44, 156-158, 
supporting the hypothesis that the presence of cartilage at 56 days in the OVX rats was a 
consequence of delayed endochondral maturation. 
We attempted to control for differences in age of the animals by using mice and 
rats at the time they become skeletally mature, based on information supplied by Harlan 
and Taconic.  It is possible that the differences we observed reflected differences in 
sexual and skeletal maturity, but it is also likely that species differences played a role.  
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We suggest that results from an assay in one animal species can be compared to another 
only with caution. 
Reduction in uterine weight and serum estrogen levels in the OVX animals 
indicated that the surgical procedure was successful.  Similarly, restoration of uterine 
weight and serum estrogen in the animals implanted with slow release estrogen capsules 
show that estrogen replacement therapy was effective.  There were some differences in 
the two species, however, that may have impacted the results.  In the mice, serum 
estrogen was not reduced at 35 days, suggesting that although the ovaries were excised, 
other sources of estrogen were available.  This may also explain the increase in ossicle 
area and marrow space observed in the mice.  By 56 days, serum estrogen was depleted 
in the OVX mice and this corresponded with a decrease in uterine weight. 
Growth of the OVX+E2 rats was delayed despite the pair feeding regimen.  
Because the OVX rats grew at the same rate as the SHAM controls, the growth 
suppression in the OVX+E2 rats must have been related to the E2-supplementation.  The 
fact that serum E2 at harvest was restored to normal levels in these animals suggests that 
the time release implants were functional.  However, E2 levels were not measured at 
times prior to harvest, so we were not able to determine if E2 release was linear or if 
serum E2 was comparable to SHAM control levels at earlier time points. Another 
possibility is trauma due to the additional surgical procedures.  How or if this reduced 
growth impacted the osteoinduction response of to DBM is not known.  The OVX mice 
had a small decrease in weight at 1 week.  The reduced hormone levels may have resulted 
in a greater difficulty in recovering from the surgical-induced stress. 
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Our observations implicate differences in the T-cell defect that is expressed by the 
athymic mice and rats used in this study.  The complex biological relationship between 
estrogen, the immune system, and bone has been well studied in rodent models.  Estrogen 
has been shown to decrease osteoclast formation 140, 141 and increase osteoclast apoptosis 
139.  It is believed that estrogen regulates osteoclast function via T-cells.  Estrogen 
deficiency induces bone loss by enhancing T-cell production of TNF-α 138 and estrogen 
prevents bone loss through TGF-β signaling in T-cells 137.  Athymic mice, which lack 
functional T-cells, do not exhibit ovariectomy-induced bone loss.  However, differences 
in the skeletal physiology of euthymic and athymic mice have been demonstrated 124, 
suggesting that bone formation is also regulated via T-cell dependent mechanisms.  For 
instance, athymic mice have lower serum calcium and alkaline phosphatase, greater 
femur density, and a lower percent ash weight of dry bone compared to euthymic mice.  
This modified skeletal physiology characterized by a lack of T-cells could, therefore, 
influence bone formation as a result of induction by DBM.  The importance of the 
immune system in bone homeostasis has also been shown in rats.  The administration of 
an immunosuppressant, cyclosporine A, induced rapid bone loss 159.  Moreover, 
ovariectomy of athymic rats has been shown to result in loss of trabecular bone volume 
and trabecular area after 2 weeks 147 due in part to the fact that functional T-cells are still 
present, although reduced in number 146. 
These observations indicate that there are important differences between the two 
animal species that could impact osteogenesis induced by DBM.  We were not able to 
compare the response of athymic animals with that of euthymic animals because human 
DBM was considered to be a xenograft, and for this reason we could not directly address 
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the role of T-cells in the osteoinduction process.  However, the present study confirms 
that there are differences in how the two animal species respond to an osteoinductive 
stimulus, suggesting that T-cells play a role.  The fact that human DBM-induced 
osteogenesis in male athymic mice produces results comparable to those seen in SHAM 
female mice for both qualitative and quantitative measurements 119, further supports the 
interpretation that the difference in the two species is T-cell related, and not due to a sex-
specific characteristic unique to females. 
In summary, this study clearly demonstrates that estrogen is important for induced 
osteogenesis.  Ovariectomy reduced, but did not completely block, osteoinduction by 
human DBM in both animal species, and estrogen replacement was able to restore the 
osteoinductive properties of human DBM.  It is important to emphasize that the effects of 
ovariectomy and estrogen on ectopic endochondral bone formation were not evident 
when using a qualitative scoring system, either in the present study using human DBM or 
in previous reports using rat DBM in ovariectomized rats 155.  Quantitative measurements 
were needed to show the decreased osteogenesis present in the ovariectomized animals.  
The qualitative score provides information on the number of sites of new bone formation, 
and if any sites are particularly large, whereas histomorphometric measurements of the 
tissues indicates whether differences in ossicle size are due to differences in the marrow 
cavity or amount of new bone.  Thus, both parameters are valuable tools for assessing 
osteoinductivity and qualitative methods alone may be inadequate as a method for 
discriminating between the relative effectiveness of materials like human DBM. 
This study also shows that there are species differences that can impact the results 
obtained when testing the osteoinduction ability of human DBM preparations, indicating 
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the need to independently validate each animal species.  Regardless of animal species, 
however, our results demonstrate that estrogen sufficiency is an important variable for the 
success use of human DBM as an osteoinductive agent in musculoskeletal therapies.  The 
present study did not address the use of human DBM in orthotopic sites, or if estrogen 
replacement can improve clinical outcomes 160-162, although the results suggest that this 
may be the case.  Further research is required to determine the role of estrogen in human 
DBM-induced osteogenesis and to develop optimal therapies for musculoskeletal 
pathologies in patients with altered hormone levels like post-menopausal women. 
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CHAPTER 5 
 
Rat Growth Plate Chondrocytes Maintain their Phenotype when 
Microencapsulated in Alginate using High Electrostatic Potential 
 
INTRODUCTION 
It is estimated that 37% of children will sustain a fracture during their childhood 
163 with 15-30% of those injuries involving the growth plate 164.  Of these injuries, over 
1% are severe enough to completely arrest limb growth and can lead to significant 
disability for the lifetime of the child 165.  A tissue engineered product could be beneficial 
for these patients as well as others affected by various osteochondrodysplasias. 
Cartilage tissue engineering has been difficult due to the propensity of 
chondrocytes to undergo a process referred to as “dedifferentiation” when expanded in 
monolayer cultures.  The lack of a three-dimensional matrix results in the chondrocytes 
expressing a fibroblastic phenotype and the down-regulation of cartilage specific 
processes 50, 90, 166.  It is believed the dedifferentiation process is a result of actin stress 
fibers that form during attachment and spreading of the cells to a two dimensional surface 
52-55.  Although cells in the resting zone of the rat growth plate are surrounded with an 
extracellular matrix similar to articular cartilage, less is known about the dedifferentiation 
process in these cells.  This is particularly true for costochondral chondrocytes, which 
have been shown to retain many of their in vivo properties through several passages in 
monolayer culture 167. 
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It has been well established that three dimensional encapsulation of chondrocytes 
in hydrogels can reverse the dedifferentiation process by maintaining the rounded 
morphology of the cell 56, 57.  It is theorized that encapsulation of chondrocytes changes 
the mechanical stresses on the cell to those seen in vivo and promotes the expression of 
cartilage specific matrix molecules.  Alginate has been one of the more commonly used 
hydrogels for encapsulation due to its inherent physical and chemical properties.  The 
linear polysaccharide chains of mannuronate and guluronate rapidly cross link in the 
presence of divalent cations such as Ca2+ to form a solid gel and entrap the chondrocytes.  
A chelating agent can then be added to break down the alginate matrix and release the 
cells and extracellular components.  Alginate encapsulation has been shown by several 
research groups to effectively reestablish a chondrocytic phenotype in a variety of 
dedifferentiated in vitro chondrocyte cultures including bovine 60, 168, rabbit 62, and 
human 59, 63, 64 articular chondrocytes.  However, there has been limited research on the 
encapsulation of growth plate chondrocytes. 
It has been shown that growth plate chondrocytes can be cultured in alginate 
beads for up to one year 169.  During this time the cells produce cartilage specific matrix 
and undergo apoptosis, which is part of the normal behavior for growth plate 
chondrocytes and necessary for endochondral bone formation.  Alginate encapsulated 
growth plate chondrocytes have also been shown to proliferate in response to growth 
factor supplementation 170 and this growth can be directed by creating microchannels 
within the alginate to mimic in situ organization of the tissue 171. 
The growth plate provides a challenging engineering problem due to the variable 
and complex anatomical geometry of the tissue.  High electrostatic potentials can be used 
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to reduce alginate bead size by disrupting the surface tension of the alginate droplets 70, 75.  
The beads produced are up to one hundred times smaller in volume than those produced 
using other disruption methods.  Beads of this size may allow minimally invasive 
injectable cell therapies that are capable of filling a range of both growth plate and 
articular defects.  The smaller bead size could reduce mass transfer limitations 172, a 
common problem among larger tissue engineered constructs that can lead to necrotic 
cores.  Moreover, the biocompatibility of alginate implants has been shown to be 
improved by decreasing bead size 74, 173. 
It is not known, however, what consequences the exposure to high electrostatic 
potential may have on chondrocyte viability and phenotypic expression.  Electrostatic 
alginate encapsulation of cells has been limited mostly to hybridomas 174 or pancreatic 
islets 175-177.  Some recent work has been done with mesenchymal stem cells 178, but this 
study did not characterize how the high electrostatic encapsulation process impacted the 
phenotype of the cells; instead it focused on the effects of cell density and alginate 
concentration on bead morphometry.  Therefore, the goal of this study was to develop a 
method for microencapsulating growth plate chondrocytes in alginate using high 
electrostatic potentials and characterize the effects of the encapsulation process on the 
phenotype of the cells. 
 
MATERIALS AND METHODS 
Rat Resting Zone Growth Plate Chondrocyte Harvest and Culture 
Costochondral resting zone growth plate chondrocytes (RC) were isolated from 
the ribs of 125g male Sprague-Dawley rats (Harlan, Indianapolis, IN).  The resting zone 
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cartilage of the rib growth plates was cut into small pieces, washed, and then digested 
with collagenase.  The digested suspension was passed though a 40μm mesh sieve and 
centrifuged at 2000 rpm for 10 minutes.  The supernatant was removed and the 
chondrocytes resuspended in full media containing Dulbecco's Modified Eagle's Medium 
(DMEM), 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 50 μg/ml L-
ascorbic acid.  Isolated primary chondrocytes were plated on T75 flasks, grown to 
confluence, and passaged using 0.25% trypsin-1mM ethylenediamine tetraacetic acid 
(EDTA).  Fourth passage RC cells were used for all experiments. 
Alginate Encapsulation and Optimization 
Ultrapure alginates (NovaMatrix, Drammen, Norway) were used to 
microencapsulate RC cells using a Nisco Encapsulator VAR V1 LIN-0043 (Nisco 
Engineering AG, Zurich, Switzerland).  Four different alginate compositions (Table 5.1) 
were used to investigate the role of molecular weight and monomer content on the 
encapsulation process and cellular phenotype.  Each alginate powder was sterilized using 
UV light and dissolved in 0.9% phosphate buffered saline (PBS) to produce a 2% (w/v) 
alginate solution.  RC cells were suspended in a minimum volume of PBS and added to 
the alginate solution resulting in 6x106 cells/ml (low density) or 50x106 cells/ml (high 
density).  The solution was then extruded through a 0.18mm (inner diameter) needle at 10 
ml/hr into a gelation solution consisting of 50 mM CaCl2 plus 150 mM glucose.  A 6 kV 
electrostatic potential between the gelation solution and needle was used to overcome the 
surface tension. 
Morphometric and viability analyses were performed on microbeads of all four 
alginate compositions (LVM, LVG, MVM, and MVG).  LVM alginate has faster 
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degradation kinetics as a result of lower molecular weight and decreased cross-linking 
due to low guluronate content.  Tissue formation has been shown to be enhanced by more 
rapid degradation of the alginate 179, 180.  For these reasons, LVM alginate was selected 
for additional experiments including mRNA measurement, light and electron microscopy, 
and in vivo implantation. 
Microbead Morphometrics 
Morphometric analysis of low density (6x106 cells/ml) microbeads of all four 
alginate compositions (LVM, LVG, MVM, and MVG) was performed using a 
computerized analysis system (Image-Pro Plus, Media Cybernetics, Silver Springs, MD).  
Areas of the sections to be measured were captured at the 10x magnification by a video 
camera.  Calibration was performed according to the instructions accompanying the 
software.  The cross sectional area and cell number were measured.  The average bead 
diameter was then calculated from the cross sectional area. 
Viability 
Viability of RC cells seeded at low density (6x106 cells/ml) in all four alginate 
compositions was measured using fluorescent confocal microscopy and a 
calcein/ethidium homodimer-1 stain (Molecular Probes, Eugene, OR).  Alginate 
encapsulated chondrocytes were cultured for 0, 1, or 2 weeks. Culture medium was 
removed and the beads washed with PBS containing 1mM CaCl2 to maintain bead 
integrity.  The samples were then incubated for 30 minutes in a PBS solution containing 1 
mM CaCl2, 4 μM ethidium homodimer-1, and 2 μM calcein.  Images were obtained using 
a LSM 510 confocal microscope (Carl Zeiss MicroImaging Inc., Thornwood, NY).  
Viability was also measured for high density (50x106 cells/ml) LVM microbeads 
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Table 5.1:  Alginate Compositions 
 
 
 
 
Table 5.2:  RT-PCR Primers for Fourth Passage Rat Growth Plate Chondrocytes 
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PCR Analysis 
After 0, 1, 3, 5, 7, or 14 days in culture, low density LVM microbeads were 
washed with saline and the alginate dissolved using 75 mM sodium citrate.  The samples 
were centrifuged to pellet the cells and the alginate removed.  RNA was extracted using 
the Qiagen miniprep kit (Qiagen, Valencia, CA) and quantified by UV spectroscopy.  
Reverse transcription PCR (RT-PCR) was used to assess expression of collagen type I, 
collagen type II, aggrecan, and the chondrocyte transcription factor, SRY-box containing 
gene (SOX-9).  RT-PCR was performed on confluent monolayer cultures as a control, 
and RNA extracted from rat native growth plate cartilage tissue or human lymphocytes 
were used as positive or negative controls, respectively, to verify the specificity of the 
primers.  RT-PCR primer information is summarized in Table 5.2. 
The total RNA sample from each sample was reverse transcribed using the First-
strand cDNA Synthesis Kit (Amersham-Biosciences, Piscataway, NJ) and the specific 
anti-sense primer for each mRNA of interest.  The cDNA was amplified using the Fisher 
PCR kit (Fisher Scientific International, Hampton, NH) and the specific sense and anti-
sense primers.  PCR conditions for each cycle included a 30 second denaturation at 94 
oC, a 60 second annealing at 50-65 oC depending on the primer used, and a 30 second 
extension at 72 oC.  The PCR-amplified products were run on 5% polyacrylamide gels 
using a buffer consisting of 0.9 M Trizma® base (tris[hydroxymethyl]aminomethane), 
0.9 M boric acid, and 20 mM EDTA. 
In vitro Histology and Transmission Electron Microscopy 
High density (50x106 cells/ml) LVM alginate microbeads were used for 
microscopy analysis to maximize the number of cells visible per section.  The microbeads 
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were cultured for 2 weeks, fixed with 2.5% gluteraldehyde in 0.1 M cacodylate buffer, 
embedded in polyacrylate resin, and sectioned.  General cell appearance and matrix 
deposition were assessed using toluidine blue and safranin-O stained sections (Winship 
Cancer Institute Pathology Core Lab, Atlanta, GA).  Ultrathin sections were examined by 
TEM to evaluate the subcellular structure of microencapsulated cells (Emory School of 
Medicine Microscopy Core, Atlanta, GA). 
Glycosaminoglycan Quantification 
The production of proteoglycans was measured in monolayer and alginate 
microbead cultures.  RC cells were either cultured as monolayers in 6-well plates or in 
low cell density LVM microbeads.  Both monolayer and microbead samples contained 
approximately 500,000 cells.  At 3, 5, 7, 10, 12, and 14 days post-confluence or post-
encapsulation, the culture media was exchanged and the amount of free 
glycosaminoglcyans (GAGs) quantified using 1,9-dimethylene blue (DMMB) dye.  
Monolayer and microbead samples were also harvested at 1 and 2 weeks and the total 
accumulated GAGs quantified.  Monolayer samples were harvested using trypsin and 
microbead samples were harvested by dissolution in 75 mM NaCitrate. 
The DMMB dye solution was prepared by mixing 16 mg of DMMB with 5 ml of 
100% ethanol.  The dissolved DMMB was then added to a 950 ml solution containing 
40.5 mM glycine and 40.5 mM NaCl.  The pH was adjusted to 1.5 using 1 M HCl to 
reduce interference by the alginate 181, and the solution brought up to 1 liter volume using 
dilute HCl.  The final absorbance of the solution was between 0.30 and 0.34 at 525 nm, 
and between 1.25 and 1.33 at 592 nm.  Chondroitin sulfate diluted in the appropriate 
solution was used a the standard:  full culture media for free GAG samples, 50% 
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trypsin:50% full media for monolayer samples, and 75mM NaCitrate with 0.05% LVM 
alginate for micobead samples.  Eight microliters of sample were aliquoted into 96-well 
plates and 200 μl of DMMB dye were added.  The samples were incubated at room 
temperature for 5 minutes and the absorbance measured at 592 nm using a microplate 
reader. 
Athymic Mouse Intramuscular Implant Model 
An athymic mouse intramuscular implant model was used to assess the in vivo 
response of the LVM alginate microbeads.  Six week old athymic nude (Nu/Nu) mice 
(Taconic, Germantown, NY) were anesthetized using isoflurane gas.  A small skin 
incision was made over the calf region of the hind limb following disinfection, and a 
pouch was prepared in the muscle by blunt dissection 119.  One gelatin capsule filled with 
50 μl alginate microbeads containing approximately 3x105 (low density) RC cells was 
inserted into the gastrocnemius muscle.  The same number of unencapsulated RC cells or 
an equal volume of blank beads with no cells were implanted as controls.  Implants were 
placed bilaterally such that each animal had two implants of the same type (N = 8 
implants; N = 4 mice/formulation).  The animals were euthanized by CO2 inhalation at 4, 
8, or 12 weeks and the legs harvested and processed for histological analysis.  An 
additional experiment using 2.5x106 (high density) RC cells was performed for 12 weeks 
using the same procedure described above.  The protocol was approved by the 
Institutional Animal Care and Use Committee at the Georgia Institute of Technology. 
In vivo Histology 
Following euthanasia at 4, 8, or 12 weeks, the whole of the calf region was 
excised to ensure complete recovery of the implant site and then fixed in 10% neutral 
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buffered formalin.  Histological processing was performed by AppTec (St. Paul, MN).  
After decalcification in 5% formic acid, tissues were embedded in paraffin, sectioned and 
stained with hematoxylin and eosin.  Cross-sectional cuts (3-4 µm each) were made at 
three different levels of the limb (3 total sections per leg) to ensure visualization of the 
implant site. 
Statistical Analysis 
The results of the morphometry, viability and GAG quantification were calculated 
as the means ± SEM for each variable.  The values for morphometry and viability 
represented measurements from ten micrographs at 10x magnification.  The GAG 
quantification values represent six individual cultures.  The amount of total free GAG 
released over time was calculated by summing the values of the current and preceding 
time points, and the variability calculated using propagation of error.  Statistical 
significance of morphometry and viability samples was determined by one or two-way 
ANOVA followed by use of Bonferroni’s modification of Student’s t-test.  Statistical 
significance of GAG quantification samples was determined by use of the Mann-Whitney 
rank sum test.  P values ≤ 0.05 were considered significant. 
 
RESULTS 
Characterization of Encapsulation Method 
The average bead diameter varied from 176±2 μm to 194±7 μm depending on the 
alginate composition used (Figure 5.1A), but there were no statistically significant 
differences among the formulations.  In addition, no significant change in bead diameter  
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Figure 5.1:  Quantitative morphometric analysis of alginate microbeads 
Fourth passage rat costochondral resting zone growth plate chondrocytes (RC) 
were suspended in several formulations of ultrapure alginate with variable molecular 
weights and compositions (LVG, MVG, LVM, MVM).  Microbeads were formed by 
extruding the suspension through a needle into an isotonic gelation bath containing 
calcium chloride and glucose.  A 6 kV electrostatic potential between the needle and bath 
was used to disrupt the surface tension and reduce bead size.  Morphometrics were 
performed using ten micrographs at 10x magnification.  (A) The average bead diameter 
directly after encapsulation was 176±2 to 194±7 μm.  There was no statistical difference 
based on alginate formulation and the bead size remained constant during the 2 week 
culture period.  (B) The average cell number per bead following encapsulation was 69±2 
to 80±4, which corresponded to the initial seeding density of 6x106 cells/ml.  There was 
no statistical difference based on alginate formulation or culture time, indicating minimal 
proliferation of the cells.  (C) The beads and cells were easily viewed by light 
microscopy and remained intact and uniform after 2 weeks.  The micrograph illustrates 
RC cells microencapsulated in LVG alginate after 2 weeks of in vitro culture. 
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Figure 5.2:  Viability of rat growth plate chondrocytes in alginate microbeads 
Fourth passage rat costochondral resting zone growth plate chondrocytes (RC) were 
microencapsulated in various alginate formulations (LVG, MVG, LVM, MVM) and the 
viability measured using fluorescent confocal microscopy and a calcein/ethidium 
homodimer-1 stain.  (A) The micrograph shows calcein stained RC cells 
microencapsulated for 2 weeks at low cell density (6x106 cells/ml) in MVM alginate.  
Viable cells were evenly distributed throughout the microbead indicating sufficient mass 
transfer to the center of the construct.  (B) The same construct stained with ethidium 
homodimer-1 shows minimal cell death after 2 weeks of culture.  (C) Viability was 
quantified using ten micrographs at 10x magnification. The initial viability was 83% to 
91% and increased significantly after 1 week to >98% for all alginate compositions.   (D) 
The effect of seeding density was determined by microencapsulating RC cells in LVM 
alginate at low (6x106 cells/ml) and high (50x106 cells/ml) density.  The initial viability 
after encapsulation was not significantly different, but after 1 week of in vitro culture 
there was more cell death observed in the high density constructs.  *P < 0.05, Initial vs. 
End Time Point. #P < 0.05, Low vs. High Cell Density. 
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was measured during the two weeks of in vitro culture.  In the low cell density 
microbeads, the initial cell number per bead was 69±2 to 75±3 (Figure 5.1B), which 
corresponded to the loading density of 6 x106 cells/ml.  No significant change in cell 
number per bead was observed over two weeks in any of the alginate compositions.  The 
beads and encapsulated cells were easily viewed by light microscopy and remained intact 
and uniform during the two weeks of culture (Figure 5.1C). 
The viability of low cell density microbeads was measured in all four alginate 
compositions using calcein (Figure 5.2A) to stain the cytoplasm of live cells and ethidium 
homodimer-1 (Figure 5.2B) to stain of the nuclei of dead cells.  The live cells were 
evenly distributed throughout the beads with an initial viability of 83% to 91% (Figure 
5.2C).  Viability increased after one week in culture to greater than 98% for all alginate 
compositions and remained constant up to two weeks.  No statistically significant 
differences in viability were observed between the different alginate compositions on cell 
viability during the in vitro culture of low cell density microbeads.  High cell density 
LVM microbeads were also cultured in vitro for 2 weeks (Figure 5.2D).  The initial 
viability of 80% was not statistically different compared to low cell density LVM 
microbeads, but after one week in culture the viability significantly decreased to 70%.  
The viability recovered during the second week of culture to 77%; however, this was still 
significantly less than the 98%+ viability seen in low cell density LVM microbeads.  
Phenotype Analysis 
Monolayer cultured RC cells expressed mRNAs for aggrecan, collagen type I and 
collagen type II (Figure 5.3A).  Alginate microencapsulated RC cells continued to  
 
 
 
87
 
Figure 5.3:  Analysis of mRNA expression of microencapsulated rat growth plate 
chondrocytes 
Reverse transcription polymerase chain reaction (RT-PCR) was used to measure 
mRNA expression of cartilage specific genes in fourth passage rat costochondral resting 
zone growth plate chondrocytes (RC).  (A) Monolayer RC cultures showed expression of 
the cartilage specific proteoglycan aggrecan, as well collagens type I and type II.  (B) RC 
cells microencapsulated at low density (6x106 cells/ml) in LVM alginate maintained a 
constant level of aggrecan, collagen type I and collagen type II expression during the 2 
week in vitro culture. 
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express constant levels of aggrecan, collagen type I, and collagen type II during the 14 
day culture period (Figure 5.3B).  SOX-9 expression was not detected in monolayer RC 
cell cultures or in alginate encapsulated cells at any of the time points during the two 
weeks of culture, but was detected in the positive controls of native rat growth plate 
cartilage. 
Morphological Analysis 
Toluidine blue staining of high density (50x106 cells/ml) microbeads after two 
weeks showed two distinct cell populations (Figure 5.4A).  One population appeared to 
be viable cells with active formation of dark staining granules, while the other population 
looked inactive.  This variation of staining could be a function of where the cells where 
sectioned or could possibly indicate cell death.  Minimal extracellular matrix deposition 
was observed in either population.  Further staining with safranin-O confirmed the lack of 
matrix deposition by the RC cells (Figure 5.4B). 
TEM analysis did not demonstrate the presence of two distinct cell populations 
indicating the pale staining seen in the histology was possibly an artifact of the histology.  
RC cells showed highly active vesicle production (Figure 5.5A) containing dense coiled 
fibers (Figure 5.5B).  In addition, the alginate matrix in contact with the RC cells 
appeared denser, indicating possible matrix deposition that was undetected with light 
microscopy (Figure 5.5C).  The cells, however, did not appear to degrade the alginate and 
exhibited minimal mitosis due to the restriction of the alginate matrix.  Moreover, they 
appeared to retract from the alginate to form a gap, potentially in the attempt to deposit 
extracellular matrix (Figure 5.5D). 
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Figure 5.4:  Light microscopy of microencapsulated rat growth plate chondrocytes 
Histological analysis was performed on fourth passage rat costochondral resting 
zone growth plate chondrocytes (RC) encapsulated at high density (50x106 cells/ml) in 
LVM alginate microbeads after 2 weeks of in vitro culture.  (A) Toluidine blue staining 
demonstrated active living cells with dark staining granules, but also a population of pale 
staining cells.  The variation of cellular staining could be the result of where the cells 
were sectioned or could indicate less active or dead cells.  There did not appear to be 
significant extracellular matrix deposition.  (B) Safranin-O staining further confirmed the 
minimal deposition of matrix. 
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Figure 5.5:  Transmission electron microscopy of microencapsulated rat growth 
plate chondrocytes 
TEM was performed on fourth passage rat costochondral resting zone growth 
plate chondrocytes (RC) microencapsulated at high density in LVM alginate following 2 
weeks of in vitro culture.  Unlike light microscopy, TEM showed only one homogenous 
cell population.  (A) RC cells appeared intact with a distinct nucleus and highly active 
vesicle production in the cytoplasm.  (B) The vesicles contained dense coiled fibers most 
likely composed of extracellular matrix components.  (C) The cell-alginate interface 
appeared denser signifying possible matrix deposition.  (D) The presence of gaps 
between the cells and alginate could also indicate an attempt by the RC cells to release 
their matrix filled vesicles by retracting from the supporting matrix. 
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Figure 5.6:  Analysis of matrix synthesis and secretion by rat growth plate 
chondrocytes 
Fourth passage rat costochondral resting zone growth plate chondrocytes (RC) 
were cultured in monolayers or low density (6x106 cells/ml) LVM microbeads, and total 
glycosaminoglycan (GAG) production quantified by 1,9-dimethylene blue (DMMB) dye.  
(A)  Monolayer and microbead samples were harvested at 1 and 2 weeks post-confluence 
or post-encapsulation and the total accumulated GAGs quantified.  Less than four 
micrograms of GAGs accumulated in monolayer RC cultures over the two week culture 
period, and there were no detectable GAG levels in microbead cultures.  (B) At 3, 5, 7, 
10, 12, and 14 days post-confluence or post-encapsulation, the culture media was 
exchanged and the amount of free GAGs quantified.  Over 40 micrograms of total GAGs 
were released into the culture media by both monolayer and microbead samples, 
indicating over ten times more GAG was released as free GAG than was sequestered as 
extracellular matrix.  There was no significant difference between the total GAGs 
released by monolayer and microbead cultures. 
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In vitro Matrix Production 
Most of the GAG synthesized by monolayer and alginate encapsulated RC cells 
was not sequestered as extracellular matrix but was instead released as free GAG into the 
culture media (Figure 5.6).  Less than four micrograms of GAGs accumulated in post-
confluent RC monolayer cultures over the two week culture period, and there were no 
detectable GAG levels in microbead cultures (Figure 5.6A).  Over 40 micrograms of total 
GAGs were released into the culture media by both monolayer and microbead samples 
during the same two week incubation time (Figure 5.6B).  There was no significant 
difference between the total GAGs released by monolayer or microbead cultures. 
In vivo Implantation 
Unencapsulated RC cell only controls formed cartilage nodules in muscle at 4, 8 
(Figure 5.7A), and 12 weeks.  Blank LVM microbeads without cells showed minimal 
degradation with highly cellular connective tissue surrounding the implants at four 
weeks.  Significant degradation debris could be seen within the surrounding fibrosis at 
eight weeks (Figure 5.7B) and 12 weeks (Figure 5.7C), but most of the microbeads 
remained intact.  Low cell density LVM beads at 4 (Figure 5.7D), 8 (Figure 5.7E), and 12 
(Figure 5.7F) weeks showed viable RC cells but no obvious chondrogenesis.  The host 
response appeared similar to blank microbead controls with significant surrounding 
fibrosis with the formation of granulation tissue at later time points.  High cell density 
LVM microbeads implanted for 12 weeks showed large lacunae signifying RC cell 
hypertrophy and differentiation (Figure 5.7G).  A large portion of the lacunae appeared 
empty suggesting apoptosis (Figure 5.7H).  Moreover, some RC cells were surrounded by 
a positively charged matrix indicating pericellular protein deposition (Figure 5.7I). 
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Figure 5.7:  Histological analysis of in vivo implanted alginate microbeads 
Fourth passage rat costochondral resting zone growth plate chondrocytes (RC) 
were microencapsulated at low (6x106 cells/ml) or high (50x106 cells/ml) density in LVM 
alginate.  The microbeads were implanted intramuscularly into athymic mice for 4, 8, or 
12 weeks.  Unencapsulated RC cells and blank microbeads were also implanted as 
controls.  (A) Unencapsulated cell only controls were capable of forming cartilage 
nodules in muscle at 4, 8, and 12 weeks.  The micrograph depicts one such nodule at 8 
weeks.  (B) The host response to blank microbeads resulted in significant surrounding 
fibrosis at 4 weeks with evidence of degradation debris by 8 weeks.  (C)  The microbeads 
showed continued degradation at 12 weeks with remodeling of the fibrosis into 
vascularized granulation tissue.  (D) Low cell density microbeads at 4 weeks showed a 
similar host response compared to blank controls but no chondrogenesis was apparent.  
(E) At 8 weeks the encapsulated RC cells still appeared viable but there was no evidence 
of chondrogenesis within or around the beads.  (F) By 12 weeks there remained no 
obvious chondrogenesis, but some of the RC cells appeared to be hypertrophied.  (G) RC 
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(Figure 5.7 continued) cells encapsulated at high cell density showed significant 
hypertrophy and the formation of lacunae at 12 weeks.  (H) The appearance of empty 
lacunae indicated possible apoptosis and therefore terminal differentiation of the RC 
cells.  (I) There was also evidence of positively charged matrix surrounding the cells 
within the lacunae, suggesting pericellular protein deposition. 
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DISCUSSION 
The physical and biological properties of alginate can vary widely depending on 
the ratio of saccharide residues and the molecular weight of the polymers.  Alginate 
composition did not appear to be an important factor in the fabrication of microbeads 
using electrostatic potential.  All four alginate compositions produced spherical 
microbeads with similar size distributions. The morphology of the beads remained 
constant for up to two weeks in culture regardless of the alginate composition.  Cell 
viability also did not vary by composition as previously reported in chondrocytes 182, 
indicating that mass transfer was not composition dependent.  However, one study on 
mouse insulinoma cells has shown an increase in metabolic rate when encapsulated in 
alginates with lower guluronate content 183, thereby suggesting composition could be an 
important factor. 
The alginate encapsulated RC cells showed minimal proliferation during the two 
week in vitro culture.  Previous research has revealed that alginate encapsulation can 
inhibit the ability of the cells to grow and divide under static culture 184.  Moreover, the 
alginate composition and degradation rate can affect proliferation as well 185.  Our results, 
however, did not exhibit any difference between the four compositions tested, which is 
consistent with other published results 182.  Prior research suggests that both fast and slow 
degradation kinetics can be beneficial for in vivo tissue formation 186, 187.  It is currently 
unclear how the composition of alginate hydrogels should be modified to optimize 
chondrogenesis. 
The degradation rate of the alginate matrix can also influence the differentiation 
pathway of the encapsulated cells 188.  The lack of proliferation could be a result of the 
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three dimensional alginate matrix stimulating normal homeostatic behavior.  Resting 
zone chondrocytes do not normally proliferate until they prepare to differentiate into 
growth zone chondrocytes.  Therefore, the static cell number could be considered 
phenotypically normal behavior for RC cells.  Another option is the three dimensional 
hydrogel matrix could be ensuing further differentiation of the cells into a hypertrophic 
phenotype.  The in vivo results we observed support this hypothesis. 
Encapsulated RC cells expressed mRNA for the relevant matrix proteins but did 
not demonstrate noteworthy matrix deposition by histology or by DMMB quantification 
of GAG production.  Monolayer cultures of RC cells were also unable to sequester GAGs 
into their extracellular matrix, indicating the ability to synthesize and secrete matrix but 
not assemble it correctly.  The plastic monolayer surface or restrictive properties of the 
alginate could have prevented secretion and accumulation of large hyaluronan molecules 
that are necessary for the anchoring of proteoglycans to the collagen fiber network.  
Previous studies have also reported this lack of GAG accumulation in alginate suspended 
chondrocyte cultures 189, 190.  The composition of the surrounding extracellular matrix is 
critical for chondrogenesis 191, and the addition of extracellular matrix molecules like 
fibronectin or collagen to the alginate gel can significantly alter the phenotype of 
chondrocytes 192.  Supplementation of the alginate matrix with additional proteins or 
proteoglycans may aid the encapsulated chondrocytes in depositing their own stable 
matrix. 
Modification of the culture conditions can enhance matrix deposition of alginate 
encapsulated chondrocytes.  Possible future studies could involve supplementation of the 
growth media with chondrogenic factors like TGF-β2, IGF-1, FGF-2 193 or BMP-2 194, 
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which have been shown to increase matrix production.  Moreover, the use of decreased 
oxygen tension can also be used to enhance chondrogenesis 168.  Xenogeneic serum has 
been shown to be less optimal than using allogeneic or autogenic serum for promoting 
chondrogenesis 195, 196.  However, the use of rat serum is not currently feasible, as fetal 
rats have a blood volume too small to effectively harvest substantial quantities for cell 
culture. 
The electrostatic potential could have had additional unknown effects on both the 
alginate and the cells.  For example, the degradation characteristics of the alginate could 
have been altered by the electrical charge.  In addition, the production of heat due to 
resistance could damage or modify certain essential cell activities.  Such studies with 
appropriate controls have not been done to date.  Our results, however, suggest the 
electrostatic potential may have minimal effect given the fact the RC cells retained a 
chondrocytic phenotype and high viability. 
The goal of producing microbeads was to enable minimally invasive injectable 
cell delivery.   We chose to implant the constructs surgically to remove the additional 
variable of mechanical loading on the cells via the injection procedure.  A significant host 
response to the implanted beads was observed despite prior literature suggesting 
otherwise 74.  It is possible the previous results were not due to size of bead, but rather a 
function of using two different methods of encapsulation. 
Implanted unencapsulated RC cells were capable of forming phenotypical 
appearing cartilage nodules in the intramuscular implant.  Implanted RC cells did not, 
however, form cartilaginous tissue in either low density or high density microbeads.  The 
RC cells at low density could have been phenotypically chondrocytes, but the lack of 
 
 
98
proliferation and minimal matrix production due to restriction by the alginate resulted in 
negligible cartilage tissue formation.  High density microbeads on the other hand 
appeared phenotypically like hypertrophic growth plate chondrocytes.  It is known that 
culture of chondrocytes in high density pellets promotes chondrogenesis 197.  The 
increased cell density could result in more interaction between cells and a higher local 
concentration of autocrine and paracrine signaling, thus promoting differentiation as seen 
in our high density cultures. 
Alginate microbeads have many potential applications for tissue engineering and 
biotechnology.  The small size allows for minimally invasive injectable cell therapies 
where the cells are protected by the hydrogel matrix, while being large enough to 
manipulate thereby permitting precise control over the number, type, and distribution of 
the cells implanted. Moreover, the decrease in volume reduces the mass transfer 
limitations associated with many constructs thus allowing for improved viability 198. 
In summary, our research shows that rat growth plate chondrocytes 
microencapsulated in alginate using a high electrostatic potential express cartilage 
specific mRNA and remain viable up to twelve weeks post implantation.  Furthermore, 
microencapsulation directly affects the differentiation of the chondrocytes resulting in a 
hypertrophic phenotype. 
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CHAPTER 6 
 
Human Articular Chondrocytes Suspended in Alginate Microbeads 
Demonstrate a Temporal Dependent Elevation in SOX-9 Expression 
 
INTRODUCTION 
Osteoarthritis is a debilitating disease that affects millions of people and costs the 
health care industry billions of dollars in treatment and disability 199.  Current treatment 
involves drug therapy to manage pain, reparative surgeries and eventually total joint 
replacement.  The ultimate goal is to design a tissue engineered cartilage graft to heal the 
arthritic lesion before total joint arthroplasty is needed.  However, the development of a 
tissue engineered product has proven to be difficult due to the complex biology of the 
chondrocyte. 
SRY (sex determining region Y)-box containing gene 9, or SOX-9, is a critical 
transcription factor in the chondrogenic pathway.  The role of SOX-9 was initially 
identified by its co-expression with the type II collagen gene (COL2A1) in cells 
undergoing chondrogenesis 200-202.  Additional work with SOX-9-/- knockout mice 
demonstrated arrestment of chondrogenesis at the mesenchymal condensation stage, 
indicating SOX-9 is the first transcription factor essential for cartilage-specific tissue 
formation 203.  SOX-9 has been shown to bind promoter regions on COL2A1 204 and may 
also directly control expression of other cartilage-specific genes like COL9A2 and 
COL11A2 203, 205.  SOX-9 activity is regulated through Sonic hedgehog (Shh) and Indian 
hedgehog (Ihh) induction of the transforming growth factor beta (TGF-β) super family, 
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which includes bone morphogenetic proteins (BMPs) 206, 207.  Fibroblast growth factors 
(FGFs) and insulin-like growth factors (IGFs) have also been shown to regulate SOX-9 
expression 208, 209, as has the Wnt signaling pathway via β-catenin 210. 
Articular chondrocytes undergo a process known as “dedifferentiation” when 
cultured in vitro as monolayers.  The lack of a three-dimensional matrix results in the 
chondrocytes expressing a fibroblast-like morphology and the down-regulation of 
cartilage-specific processes including expression of SOX-9, collagen type II and 
aggrecan 50, 51. The dedifferentiation process is believed to be the result of actin stress 
fibers that form during attachment and spreading of the cells to a two dimensional surface 
52-55. 
It has been established that three-dimensional suspension of chondrocytes in 
hydrogels can reverse the dedifferentiation process by maintaining the rounded 
morphology of the cell 56, 57.  Alginate has been one of the more commonly used 
hydrogels for encapsulation due to its ability to rapidly cross link in the presence of 
divalent cations such as Ca2+ to form a solid gel and entrap the chondrocytes.  A 
chelating agent can then be added to break down the alginate matrix and release the cells 
and extracellular matrix.  Alginate suspension has been reported by several research 
groups to be effective at redifferentiating in vitro expanded human articular chondrocytes 
(HACs) 63, 64, 211.  Moreover, it has been shown to promote differentiation of human 
mesenchymal stem cells towards a chondrocytic lineage 212, 213. 
High electrostatic potentials can be used to reduce alginate bead size by disrupting 
the surface tension of the alginate droplets 70, 75.  The microbeads produced with this 
technique are up to one hundred times smaller in volume than those created using other 
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disruption methods, and may allow minimally invasive injectable cell therapies that are 
capable of filling a range of articular defects.  Moreover, the smaller bead size could 
reduce mass transfer limitations 172, a common problem among larger tissue engineered 
constructs that can lead to necrotic cores.  Biocompatibility of alginate implants has also 
been shown to be improved by decreasing bead size 74, 173. 
It is not known, however, what consequences the exposure to high electrostatic 
potential may have on chondrocyte viability and phenotypic expression.  Electrostatic 
alginate encapsulation of cells has been limited mostly to hybridomas 174 or pancreatic 
islets 175-177.  Some recent work has been done with mesenchymal stem cells 178, but this 
study did not characterize how the high electrostatic encapsulation process impacted the 
phenotype of the cells; instead it focused on the effects of cell density and alginate 
concentration on bead morphometry.  Therefore, the goal of this study was to determine 
if electrostatic potential could be used to produce alginate microbeads containing viable 
HAC, and to assess the effects microencapsulation on the phenotype of the cells. 
 
MATERIALS AND METHODS 
Human Articular Chondrocyte Source and Culture 
Articular cartilage was isolated from the femoral condyles and tibial plateaus of 
human donors made available due to autopsy 214.  Donors had no known history of joint 
disease and histological analysis was performed at the time of isolation to confirm the 
absence of any pathologies.  The articular cartilage was cut into small pieces and washed 
twice for 20 minutes with Hanks’ balanced salt solution (HBSS) containing 1% penicillin 
and streptomycin.  The washed cartilage was digested for 1 hour with 0.25% trypsin-1 
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mM ethylene diamine tetraacetic acid (EDTA), followed by treatment with 0.2% 
collagenase for 3 hours.  All enzymes were prepared in HBSS.  The digested suspension 
was passed though a 40 μm mesh sieve and centrifuged at 2000 rpm for 10 minutes.  The 
supernatant was removed and the chondrocytes were resuspended in full media 
containing 88% Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin, and 1% L-ascorbic acid. 
Isolated primary human articular chondrocytes (HACs) were plated on T75 flasks, 
grown to confluence, and harvested using 0.25% trypsin-1 mM EDTA.  The cell 
suspension was centrifuged at 2000 rpm for 10 minutes, the supernatant removed, and the 
cells resuspended in cold DMEM, 20% FBS, 1% penicillin/streptomycin, and 5% 
dimethyl sulfoxide (DMSO).  The chondrocytes were then frozen at –80oC and shipped 
overnight from La Jolla, CA to Atlanta, GA.  The first passage chondrocytes were 
thawed, centrifuged, resuspended in full media and plated on T75 flasks.  The cultures 
were grown to confluence and passaged twice as above.  Third passage HAC cells were 
used for all experiments. 
Characterization of Cell Source 
Three male and three female donors between the ages of 16-39 were used to 
characterize the monolayer expanded articular chondrocyte cell source.  Reverse 
transcription polymerase chain reaction (RT-PCR) was used to assess the phenotype of 
the third passage HAC by measuring the mRNA expression of aggrecan, collagen type I, 
collagen type II, cartilage oligomeric matrix protein (COMP), and SOX-9.  Total RNA 
was extracted from the chondrocyte cultures with Trizol reagent.  Lipophilic 
contaminants were removed by adding chloroform and centrifuging for 25 minutes at 
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4700 rpm.  The aqueous phase was then washed with isopropyl alcohol to precipitate the 
RNA, and centrifuged for 20 minutes at 4700 rpm to form a pellet.  The pellet was 
washed with cold 70% ethanol and centrifuged for 15 minutes at 4700 rpm.  The 
supernatant was removed and the pellet allowed to air dry.  The RNA was then dissolved 
in diethylpyrocarbonate (DEPC) treated water and the purity and quantity was 
determined by UV spectrophotometry.  RNA extracted from native human articular 
cartilage tissue or human lymphocytes was used as positive or negative controls, 
respectively, to verify the specificity of the aggrecan, collagen type II, COMP, and SOX-
9 primers.  Cultured human fibroblasts were used as a positive control from collagen type 
I primers, with human lymphocytes once again serving as a negative control.  RT-PCR 
primer information is summarized in Table 6.1. 
The total RNA sample from each sample was reverse transcribed using the First-
strand cDNA Synthesis Kit (Amersham-Biosciences, Piscataway, NJ) and the specific 
anti-sense primer for each mRNA of interest.  The cDNA was amplified using the Fisher 
PCR kit (Fisher Scientific International, Hampton, NH) and the specific sense and anti-
sense primers.  PCR conditions for each cycle included a 30 second denaturation at 94 
oC, a 60 second annealing at 50-65 oC depending on the primer used, and a 30 second 
extension at 72 oC.  The PCR-amplified products were run on 5% polyacrylamide gels 
using a buffer consisting of 0.9 M Trizma® base (tris[hydroxymethyl]aminomethane), 
0.9 M boric acid, and 20 mM EDTA. 
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Table 6.1:  RT-PCR Primers for Third Passage Human Articular Chondrocytes 
 
 
 
 
Table 6.2:  Real Time RT-PCR Primers for Human Articular Chondrocytes 
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Alginate Microencapsulation 
Ultrapure LVM alginate (NovaMatrix, Drammen, Norway) with a molecular 
weight of 130,000 g/mole and a 44% guluronate content was used to microencapsulate 
HACs using a Nisco Encapsulator VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, 
Switzerland).  LVM alginate has faster degradation kinetics as a result of lower molecular 
weight and decreased cross-linking due to low guluronate content.  Chondrogenesis has 
been shown to be enhanced by more rapid degradation of the alginate 179, 180.  The LVM 
alginate powder was sterilized using UV light and dissolved in 0.9% phosphate buffered 
saline (PBS) to produce a 2% (w/v) alginate solution.  HAC cells were suspended in a 
minimum volume of PBS and added to the alginate solution resulting in 6x106 cells/ml 
(low density) or 50x106 cells/ml (high density).  The solution was then extruded through 
a 0.18mm (inner diameter) needle at 10 ml/hr into a gelation solution consisting of 50 
mM CaCl2 plus 150 mM glucose.  A 6 kV electrostatic potential between the gelation 
solution and needle was used to overcome the surface tension.  This encapsulation 
process produced spherical alginate microbeads approximately 180 μm in diameter as 
previously described in Chapter 5. 
Viability 
Viability of chondrocytes seeded at low cell density (6x106 cells/ml) and high cell 
density (50x106 cells/ml) in LVM alginate was measured using fluorescent confocal 
microscopy and a calcein/ethidium homodimer-1 stain (Molecular Probes, Eugene, OR).  
Alginate encapsulated chondrocytes were cultured for 0, 1, or 2 weeks in 6-well plates 
and media were changed at days 3, 5, 7, 10, and 12.  At time of measurement, culture 
media were removed and the beads washed with PBS containing 1mM CaCl2 to maintain 
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bead integrity.  The samples were then incubated for 30 minutes in a PBS solution 
containing 1 mM CaCl2, 4 μM ethidium homodimer-1, and 2 μM calcein.  Images were 
obtained using a LSM 510 confocal microscope (Carl Zeiss MicroImaging Inc., 
Thornwood, NY). 
In vitro Histology and Transmission Electron Microscopy 
High cell density (50x106 cells/ml) LVM alginate microbeads were used for 
microscopy analysis to maximize the number of cells visible per section.  The microbeads 
were cultured for 2 weeks as above, fixed with 2.5% gluteraldehyde in 0.1 M cacodylate 
buffer, embedded in polyacrylate resin, and sectioned.  General cell appearance and 
matrix deposition were assessed using toluidine blue and safranin-O stained sections 
(Winship Cancer Institute Pathology Core Lab, Atlanta, GA).  Ultrathin sections were 
examined by TEM to evaluate the subcellular structure of microencapsulated cells 
(Emory School of Medicine Microscopy Core, Atlanta, GA). 
Effect of Microencapsulation on Phenotype 
After 0, 1, 3, 5, 7, or 14 days in culture, low cell density LVM microbeads were 
washed with saline and the alginate dissolved using 75 mM sodium citrate.  The samples 
were centrifuged to pellet the cells and the alginate removed.  RNA was extracted using 
the Qiagen miniprep kit (Qiagen, Valencia, CA) and quantified by UV spectroscopy.  
RT-PCR was used to assess expression of collagen type I, collagen type II, aggrecan, 
COMP, and SOX-9. 
HACs were either cultured as monolayers in 6-well plates or in low cell density 
LVM microbeads.  After 0, 1, 4, or 7 days post-confluence or post-encapsulation, cells 
were harvested and the RNA extracted using the Qiagen miniprep kit (Qiagen, Valencia, 
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CA) and quantified by UV spectroscopy.  Quantitative real time RT-PCR was used to 
measure changes in aggrecan and SOX-9 mRNA expression.  Previously published real 
time RT-PCR primers were used 215, 216, and the information is summarized in Table 6.2.  
The total RNA sample from each sample was reverse transcribed as above.  Real time 
PCR was performed on an i-cycler (Bio-Rad Laboratories, Hercules, CA) using the 
software I-cycler iQ, version 3.0a.  The cDNA was amplified for 40 cycles in the 
presence of the fluorophore SYBR Green (Bio-Rad Laboratories, Hercules, CA).  PCR 
conditions for each cycle included a 30 second denaturation at 94 oC, a 30 second 
annealing at 50-65 oC depending on the primer used, and a 30 second extension at 72 oC.  
The house keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used 
to normalize the content of cDNA for each sample. 
Glycosaminoglycan Quantification 
The production of proteoglycans was measured in monolayer and alginate 
microbead cultures.  HACs were either cultured as monolayers in 6-well plates or in low 
cell density LVM microbeads.  Both monolayer and microbead samples contained 
approximately 500,000 cells.  At 3, 5, 7, 10, 12, and 14 days post-confluence or post-
encapsulation, the culture media was exchanged and the amount of free 
glycosaminoglcyans (GAGs) quantified using 1,9-dimethylene blue (DMMB) dye.  
Monolayer and microbead samples were also harvested at 1 and 2 weeks and the total 
accumulated GAGs quantified.  Monolayer samples were harvested using trypsin and 
microbead samples were harvested by dissolution in 75 mM NaCitrate. 
The DMMB dye solution was prepared by mixing 16 mg of DMMB with 5 ml of 
100% ethanol.  The dissolved DMMB was then added to a 950 ml solution containing 
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40.5 mM glycine and 40.5 mM NaCl.  The pH was adjusted to 1.5 using 1 M HCl to 
reduce interference by the alginate 181, and the solution brought up to 1 liter volume using 
dilute HCl.  The final absorbance of the solution was between 0.30 and 0.34 at 525 nm, 
and between 1.25 and 1.33 at 592 nm.  Chondroitin sulfate diluted in the appropriate 
solution was used a the standard:  full culture media for free GAG samples, 50% 
trypsin:50% full media for monolayer samples, and 75mM NaCitrate with 0.05% LVM 
alginate for micobead samples.  Eight microliters of sample were aliquoted into 96-well 
plates and 200 μl of DMMB dye were added.  The samples were incubated at room 
temperature for 5 minutes and the absorbance measured at 592 nm using a microplate 
reader. 
Response to TGF-β1 
HACs were either cultured as monolayers in 6-well plates or in low cell density 
LVM microbeads.  At 1 week post-confluence or post-encapsulation, cells were treated 
with 0.2, 1.0, or 5.0 ng/ml TGF-β1 for 24 hours prior to harvest.  At harvest, low cell 
density LVM microbeads were washed with saline and the alginate dissolved using 75 
mM sodium citrate.  The samples were centrifuged to pellet the cells and the alginate 
removed.  Monolayer samples were harvested using 0.25% trypsin-1 mM EDTA.  The 
cell suspension was centrifuged and the cell pellet washed with media and PBS.  RNA 
was extracted from monolayer and microbeads samples using the Qiagen miniprep kit 
(Qiagen, Valencia, CA) and quantified by UV spectroscopy.  Quantitative real time RT-
PCR was used to measure changes in aggrecan and SOX-9 mRNA expression as 
described above. 
Statistical Analysis 
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The results of the viability, real time PCR, and GAG quantification were 
calculated as the means ± SEM for each variable.  The values for viability represented 
measurements from ten micrographs at 10x magnification.  The real time PCR and GAG 
quantification values represent six individual cultures.  The amount of total free GAG 
released over time was calculated by summing the values of the current and preceding 
time points.  The variability of summed GAG time points was calculated using 
propagation of error.  Statistical significance of viability and real time PCR samples was 
determined by one or two-way ANOVA followed by use of Bonferroni’s modification of 
Student’s t-test.  Statistical significance of GAG quantification samples was determined 
by use of the Mann-Whitney rank sum test.  P values ≤ 0.05 were considered significant. 
 
RESULTS 
Characterization of Cell Source 
Expansion of human articular chondrocytes for three passages in monolayer 
culture resulted in partial loss of phenotypic expression.  The chondrocytes retained their 
ability to express aggrecan core protein and COMP mRNA, but lost expression of 
collagen type II mRNA (Figure 6.1).  In addition, the cells showed a strong expression 
collagen type I mRNA indicating a dedifferentiated phenotype.  Despite loss of collagen 
type II expression, HAC from all six donors tested maintained expression SOX-9.  
Viability of Microencapsulated HACs 
Cell viability was only minimally affected during microencapsulation.  The live 
cells appeared evenly distributed throughout the beads with an initial viability of 89% in  
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Figure 6.1:  Analysis of mRNA expression of third passage human articular 
chondrocytes 
Reverse transcription polymerase chain reaction (RT-PCR) was used to measure 
mRNA expression of cartilage specific genes in third passage monolayer expanded 
human articular chondrocytes (HACs).  Cells were harvested from three male and three 
female donors between the ages of 16-39.  RNA extracted from native human articular 
cartilage tissue (aggrecan, collagen type II, COMP, and SOX-9) or cultured human 
fibroblasts (collagen type I) were used as positive controls.  Human lymphocyte RNA 
served as a negative control.  HACs from all six donors showed a similar expression 
profile exhibiting a partially dedifferentiated phenotype with no detectable collagen type 
II expression and strong expression of collagen type I.  The expanded third passage HAC 
maintained expression of aggrecan and COMP, and SOX-9. 
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Figure 6.2:  Viability of human articular chondrocytes in alginate microbeads 
Third passage human articular chondrocytes (HACs) were microencapsulated in 
LVM alginate at low (6x106 cells/ml) and high (50x106 cells/ml) cell density.  Viability 
was measured using calcein/ethidium homodimer-1 stain and quantified by fluorescent 
microscopy using ten micrographs at 10x magnification.  The initial viability was greater 
in low cell density microbeads, but the viability of high density microbeads increased to 
similar levels after one week of culture.  A viability of ~90% was maintained by both 
seeding densities during the second week of culture.  *P < 0.05, Initial vs. End Time 
Point. #P < 0.05, Low vs. High Cell Density. 
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Figure 6.3:  Analysis of mRNA expression of microencapsulated human articular 
chondrocytes 
The phenotype of third passage monolayer expanded human articular 
chondrocytes (HACs) suspended at low density (6x106 cells/ml) in LVM alginate 
microbeads was assessed using reverse transcription polymerase chain reaction (RT-
PCR) to measure mRNA expression of cartilage specific genes.  (A) Samples were 
harvested at 0, 1, 3, 5, 7, and 14 days post-encapsulation.  HACs did not redifferentiate as 
evidenced by the lack of collagen type II expression.  Encapsulated HAC continued to 
express aggrecan, COMP and SOX-9 during the two week culture period.  (B) 
Quantitative real time RT-PCR demonstrated a decrease in aggrecan expression in both 
monolayer and encapsulated cultures.  Depression of aggrecan levels over time was more 
pronounced in alginate microbeads.  (C) SOX-9 expression showed a biphasic response 
in alginate microbeads with an initial increase followed by a decrease to control levels 
after 24 hours.  At later time points SOX-9 mRNA expression remained significantly 
depressed compared to the initial peak but was elevated over monolayer controls.  *P < 
0.05, Initial vs. End Time Point.  #P < 0.05, Monolayer vs. Alginate Culture. 
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low cell density microbeads (Figure 6.2).  Viability remained constant up to two weeks 
with no statistically significant differences observed.  At high density, the initial viability 
of 73% was significantly lower compared to low density cultures.  However, after one 
week in culture the viability increased to that of low density cultures and remained 
constant for up to two weeks. 
Effect of Microencapsulation on Phenotype 
Alginate microencapsulated HAC cells maintained the same mRNA expression 
profile as seen in monolayer cultures (Figure 6.3A).  The encapsulated cells continued 
expression of aggrecan, COMP, and SOX-9 for up to 14 days in culture.  Encapsulation 
did not reestablish collagen type II mRNA expression and there was not a significant 
decrease in the expression of collagen type I.  In addition, there appeared to be a decrease 
in the expression of both aggrecan and SOX-9 mRNA, which was confirmed by 
quantitative real time RT-PCR.  There was a significant decrease in aggrecan mRNA 
levels in both post-confluent monolayer cultures and alginate microbeads (Figure 6.3B).  
In addition, this decrease in aggrecan expression occurred earlier and was more 
pronounced in the microbead cultures.  The mRNA levels of SOX-9 showed an initial 
increase immediately after encapsulation (Figure 6.3C).  However, SOX-9 levels then 
significantly decreased after 24 hours post-encapsulation to levels similar to monolayer 
controls.  SOX-9 mRNA expression was increased over monolayer. 
Histological Analysis 
Toluidine blue staining of high density (50x106 cells/ml) beads after two weeks in 
culture showed HAC with active formation of dark staining granules (Figure 6.4A).  In  
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Figure 6.4:  Light microscopy of microencapsulated human articular chondrocytes 
Histological analysis was performed on third passage human articular 
chondrocytes (HACs) encapsulated at high density (50x106 cells/ml) in LVM alginate 
microbeads after two weeks of in vitro culture.  (A) Toluidine blue staining demonstrated 
active living cells surrounded by a dark staining ring.  (B) Further staining with safranin-
O confirmed the presence of pericellular matrix deposition by the suspended HAC. 
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Figure 6.5:  Tranmission electron microscopy of microencapsulated human 
articular chondrocytes 
TEM was performed on third passage human articular chondrocytes (HACs) 
microencapsulated at high density (50x106 cells/ml) in LVM alginate following two 
weeks of in vitro culture.  (A) HACs cells appeared intact with a distinct nucleus and 
highly active vesicle production in the cytoplasm.  (B) The vesicles contained dense 
coiled fibers most likely composed of extracellular matrix components.  In addition, the 
cell-alginate interface appeared denser signifying possible matrix deposition.  (C) The 
presence of gaps between the cells and alginate could also indicate an attempt by the RC 
cells to release their matrix filled vesicles by retracting from the supporting matrix.  (D)  
Minimal mitosis was observed due to the restrictive nature of the alginate which forced 
dividing HAC to occupy the same initial space. 
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Figure 6.6:  Analysis of matrix synthesis and secretion by human articular 
chondrocytes 
Third passage human articular chondrocytes (HACs) were cultured in monolayers 
or low density (6x106 cells/ml) LVM microbeads, and total glycosaminoglycan (GAG) 
production quantified by 1,9-dimethylene blue (DMMB) dye.  (A)  Monolayer and 
microbead samples were harvested at 1 and 2 weeks post-confluence or post-
encapsulation and the total accumulated GAGs quantified.  Less than four micrograms of 
GAGs accumulated in monolayer HAC cultures over the two week culture period, and 
there were no detectable GAG levels in microbead cultures.  (B) At 3, 5, 7, 10, 12, and 14 
days post-confluence or post-encapsulation, the culture media was exchanged and the 
amount of free GAGs quantified.  Over 200 micrograms of total GAGs were released into 
the culture media by both monolayer and microbead samples, indicating over fifty times 
more GAG was released as free GAG than was sequestered as extracellular matrix.  
There was no significant difference between the total GAGs released by monolayer and 
microbead cultures. 
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addition, the cells were surrounded by a dark staining ring indicating possible matrix 
production. Further staining with safranin-O stain suggested that the cells were producing 
a local matrix of proteoglycans (Figure 6.4B).  A negative control of breast cancer cells 
encapsulated for one day did not show dark pericellular staining, signifying the 
observations were not an artifact of the histological processing. 
TEM confirmed the histological observations in HAC cells and also showed 
highly active vesicle production (Figure 6.5A), containing dense coiled fibers (Figure 
6.5B).  Moreover, the alginate matrix in contact with HAC appeared denser, further 
demonstrating the deposition of pericellular matrix.  The HAC did not appear to be 
breaking down the alginate; instead they appeared to retract from the alginate to form a 
gap, potentially to deposit extracellular matrix (Figure 6.5C).  The HAC exhibited 
minimal mitosis due to the restriction of the alginate matrix and the dividing cells were 
forced to occupy the same space as the original cell or fill spaces vacated by dead cells 
(Figure 6.5D). 
In vitro Matrix Production 
Most of the GAG synthesized by monolayer and alginate encapsulated HAC cells 
was not sequestered as extracellular matrix but was instead released as free GAG into the 
culture media (Figure 6.6).  Less than four micrograms of GAGs accumulated in post-
confluent RC monolayer cultures over the two week culture period, and there were no 
detectable GAG levels in microbead cultures (Figure 6.6A).  Over 200 micrograms of 
total GAGs were released into the culture media by both monolayer and microbead  
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Figure 6.7:  Effect of TGF-β1 on third passage human articular chondrocytes 
Third passage human articular chondrocytes (HACs) suspended in LVM alginate 
microbeads were cultured for one week post-encapsulation before treatment with 0.2, 1.0, 
or 5.0 ng/ml TGF-β1 for 24 hours.  Third passage HACs monolayer controls were 
cultured for one week post-confluence and also treated with TGF-β1.  RNA was 
extracted and real time reverse transcription PCR (real time RT-PCR) was performed.  
All samples were negative for collagen type II expression.  (A) Aggrecan expression was 
not significantly affected by alginate encapsulation or TGF-β1 treatment.  (B) SOX-9 
expression was not affected by TGF-β1 treatment but was significantly elevated 
compared to monolayer controls.  *P < 0.05, Monolayer vs. Alginate Culture. 
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samples during the same two week incubation time (Figure 6.6B).  There was no 
significant difference between the total GAGs released by monolayer or microbead 
cultures. 
Response to TGF-β1 
Treatment with TGF-β1 did not have a significant effect on redifferentiating the 
encapsulated HAC at any of the dosages tested.  Collagen type II mRNA was not 
detected after treatment with TGF-β1 nor was there any effect on aggrecan or SOX-9 
expression (Figure 6.7A and 6.7B).  However, SOX-9 expression was significantly 
elevated in encapsulated cells compared to monolayer controls (Figure 6.7B). 
 
DISCUSSION 
Alginate microencapsulation using an electrostatic potential was not able to 
reestablish a collagen type II expressing phenotype of third passage HAC after two weeks 
of in vitro culture.  Although a majority of studies using alginate encapsulation of human 
articular chondrocytes have reported redifferentiation, it has also been shown that three 
dimensional encapsulation can be insufficient.  Alginate encapsulation alone was unable 
to redifferentiate human septal chondrocytes expanded beyond first passage 217 or HAC 
expanded to third passage 218.  Several factors have been identified that may account for 
this variation. 
The serum conditions used for in vitro culture of chondrocytes have been shown 
to be critical for phenotype development.  The expression of collagen type II by alginate 
suspended second passage HAC was shown to be highly dependent upon the lot of FBS 
used to culture the cells 219.  Moreover, it has been established that the use human serum 
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is more beneficial than FBS for promoting a chondrocytic phenotype in human 
chondrocytes 196, 220.  Serum-free culture of chondrocytes has also been investigated to 
simulate the avascular environment of cartilage tissue.  Chondrogenesis of human 
mesenchymal stem cells was shown to be enhanced under serum-free conditions 221.  In 
addition, the use of serum-free media supplemented with specific chondrogenic factors 
like IGF-1, FGF-2, and TGF-β2 was superior to FBS for supporting redifferentiation of 
expanded human auricular chondrocytes 208, 222.   
Cartilage tissue has a low oxygen tension due to its lack of vasculature, and it is 
well-known that using a more physiologic oxygen tension when culturing chondrocytes 
improves the expression of cartilage specific genes 168, 218.  The smaller size of the 
microbeads results in a more uniform gradient of nutrient diffusion throughout the 
construct 70.  This would be beneficial for most types of tissue by reducing mass transfer 
limitations and decreasing the development of necrotic cores.  However, this may have 
been counter productive for promoting a chondrocytic phenotype, which favors a nutrient 
poor environment.  This hypothesis is further supported by the fact that increasing 
chondrocyte seeding density of alginate constructs, and therefore the competition for 
nutrients, leads to improved cartilage tissue formation 67.  The mRNA expression profile 
of high cell density and low cell density microbeads could be significantly different based 
on these previous studies and should be investigated.  Moreover, the possible temporal 
changes observed in aggrecan and SOX-9 expression may in part be due to an initial 
hypoxia or lack of nutrients during the encapsulation process. 
Despite the lack of collagen type II expression, the HAC suspended in alginate 
microbeads maintained strong levels of aggrecan and COMP, and also showed increased 
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levels of SOX-9 compared to confluent monolayer controls.  It has been well established 
that alginate suspension increases SOX-9 levels 208, 223, 224, but it has also been reported 
that a high expression of SOX-9 does not necessarily correlate to an increase in collagen 
type II expression 225.  Recent work has suggested that SOX-9 exerts a bi-functional 
effect on COL2A1 that is dependent on the differentiation state of the chondrocyte 204.  
Low levels of SOX-9 overexpression enhanced COL2A1 gene transcription of both 
primary and second passage rabbit articular chondrocytes, but high levels of SOX-9 
overexpression were inhibitory.  Further dedifferentiation of the chondrocytes to fifth 
passage resulted in depressed COL2A1 transcriptional activity that was independent of 
SOX-9 levels.  Moreover, osteoarthritic chondrocytes, which exhibit similar cellular 
biology to dedifferentiated chondrocytes, have an up-regulation of COL2A1 despite a 
decrease in SOX-9 levels 226. 
Supplementation of the growth media with various chondrogenic factors has 
demonstrated the ability to enhance redifferentiation of expanded human articular 
chondrocytes 194, 219, 227, 228.  TGF-β1 plays a role in early chondrogenesis 229 and has been 
shown to be important in the differentiation of mesenchymal stem cells toward a 
chondrogenic lineage 212, 230.  In addition, TGF-β1 is responsible for preventing terminal 
differentiation of chondrocytes towards a hypertrophic and apoptotic pathway 231, 232.  In 
the present study, however, TGF-β1 treatment did not have any effect on aggrecan, 
collagen type II, or SOX-9 levels in HACs suspended in alginate microbeads.  TGF-β1 
was selected based on our previous work with rat growth plate chondrocytes which 
showed enhanced differentiation via interacting PKC and PKA mediated mechanisms 89, 
233, 234.  Improved redifferentiation of alginate suspended HAC has been demonstrated 
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using TGF-β1 219, 235, but it has also been reported that TGF-β1 can be ineffective and 
even inhibitory 236, 237.  These varying observations may be due to the precise state of 
dedifferentiation of the chondrocytes based on species, passage number and culture 
conditions. 
The formation of microbeads has many applications for tissue engineering and 
biotechnology.  The small size allows for minimally invasive injectable therapies where 
the cells are protected by the hydrogel matrix, while also being large enough to easily 
manipulate and permit precise control over the number, type, and distribution of cells 
implanted.  The electrostatic encapsulation process was well tolerated by the HACs as 
signified by their viability and expression of cartilage specific molecules.  However, the 
HACs did not redifferentiate when suspended in the microbeads.  Further studies are 
needed to determine what biological effects the alteration in mass transport had on the 
microbead system. 
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CHAPTER 7 
 
Conclusions and Future Perspectives 
 
This work has established that 17β-estradiol (E2) plays a significant role in 
orthopaedic tissue engineering and regenerative medicine.  We have shown that E2 has an 
important sex-specific function in regulating the phenotype of human articular 
chondrocytes.  Moreover, the osteoinductive properties of demineralized bone matrix 
(DBM) are inhibited in an estrogen deficient environment.  However, there are still 
numerous unanswered questions regarding sexual dimorphism and cartilage regeneration. 
The most important next step is identifying what receptor protein is mediating the 
rapid membrane-associated effects of E2.  This would allow further characterization and 
understanding of this non-traditional steroid signaling mechanism.  Furthermore, it may 
lead to the discovering of other steroid membrane receptors including membrane 
receptors for androgens.  It would also be of interest to investigate if this sex-specific E2 
membrane effect was present in all tissues including other types of cartilage like elastic 
auricular tissue or intervertebral discs.  Perhaps different tissues express variable 
concentrations and isoforms of sex steroid membrane receptors that control their sexual 
dimorphism.  If this is the case, then the development of drugs that are more beneficial 
for only men or women may be a reality in the future.  Moreover, it may be possible to 
design compounds that only activate the membrane steroid receptors and not the 
traditional cytoplasmic receptors.  This could be very beneficial for the treatment of post-
menopausal osteoarthritis and osteoporosis while not increasing the risks commonly 
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associated with hormone replacement therapy like increased incidence of breast and 
ovarian cancers. 
We were unable to produce a tissue engineered cartilage implant to determine 
what role E2 could have on in vivo tissue formation.  However, we did uncover many 
interesting differences between human articular chondrocytes (HAC) and rat 
costochondral resting zone growth plate chondrocytes (RCs) and their response to 
alginate microencapsulation.  First, RC cells did not express SOX-9 but still showed 
expression of collagen type II, while HAC had the opposite expression profile.  This lack 
of correlation between collagen type II and SOX-9 expression accentuates the complexity 
of chondrocyte biology.  Further study is needed to determine what effects species, 
cartilage type, and monolayer expansion have on the activity of SOX-9.  Second, HACs 
had a significantly better survival rate at high cell densities than RC cells.  This is not 
completely unexpected as the resting zone of the growth plate is accustomed to receiving 
more nutrients than articular cartilage due to the vasculature of the surrounding bone.  
However, this difference highlights that there are important biological differences 
between the resting zone growth plate and articular cartilage even though they both are 
hyaline cartilage.  Third, HAC produced significantly more glycosaminoglcyans (GAGs) 
compared to RC cells.  However, the retention of secreted GAGs was minimal in both 
cell types.   
Previous studies have also reported this lack of GAG accumulation in alginate 
suspended chondrocyte cultures 189, 190.  One possible explanation is that the chondrocytes 
are not generating or correctly assembling the necessary hyaluronic acid (HA) backbone 
to aggregate the proteoglycans produced.  Moreover, there could be a deficiency in link 
 
 
125
proteins that are necessary for binding of the proteoglycans to HA.  The collagen scaffold 
is also important for the accumulation of GAGs via the anchoring of HA.  The lack of 
collagen type II expression by HACs could have partially been responsible for our 
observations.  In addition, we did not measure the expression of other cartilage specific 
collagens like type VI, type IX, and type XI.  The RCs could have been deficient in these 
collagens even though they showed expression of collagen type II and thereby potentially 
explain their inability to aggregate proteoglycans.  It is also possible that the inability to 
sequester GAGs was the result of increased activity of degradation enzymes like matrix 
metalloproteinases (MMPs) and aggrecanases.  This theory is further supported by the 
fact that chondrocytes isolated from arthritic cartilage have an increased expression of 
degradation enzymes, and dedifferentiated chondrocytes have been shown to exhibit 
similar biochemistry to osteoarthritic chondrocytes.  The composition of the surrounding 
extracellular matrix is critical for chondrogenesis 191, and the addition of extracellular 
matrix molecules like fibronectin or collagen to the alginate gel can significantly alter the 
phenotype of chondrocytes 192. 
Alginate microencapsulation was not able to redifferentiate second or third 
passage HACs using our culture conditions.  As previously mentioned in Chapter 6, there 
are many possible modifications that could be investigated to enhance chondrogenesis of 
the alginate microbeads.  One of the more important parameters appears to be the culture 
serum.  Screening different lots of fetal bovine serum for redifferentiation potential may 
be required to maximize the chondrocytic phenotype of suspended HACs.  In addition, it 
would of interest to study the effects of human serum, especially if there are sex-specific 
effects that are dependent on serum donor sex.  Serum-free conditions that simulate the 
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avascularity of cartilage have also been shown to enhance redifferentiation, especially 
when supplement with growth factors.  Speaking of which, we could examine the effects 
of other growth factors besides TGF-β1 like BMP-2, TGF-β2, IGF-1, and FGF-2 either 
alone or in combinations.  Finally, there is the application of reduced oxygen tension to 
further mimic the normal physiologic cartilage environment.  This requires the 
development of a specialized incubation chamber, but oxygen tension has been well 
established as a major component affecting chondrogenesis in vitro and should be 
explored with respect to our microbead system. 
There has been minimal experimentation on the how alginate composition affects 
encapsulated cells.  Our studies did not detect any differences based on composition, but 
we limited our measurements to viability.  Although there have not been any reports of 
cells interacting biologically with alginate, the composition of alginate does determine 
the pore size of the matrix.  This is very important in determining how much space the 
cells have to deposit matrix, as well as for defining the diffusivity of large molecules like 
growth factors and matrix components into and out of the microbeads.  The addition of 
other matrix molecules to the alginate suspension could also assist in further simulating a 
normal environment for the chondrocytes. This is especially relevant for pericellular 
components like fibronectin and collagen type VI, which would aid in the 
reestablishment of biochemical and biomechanical signals between the chondrocytes and 
extracellular matrix. 
The chondrocytes encapsulated within alginate microbeads were unable to form 
hyaline cartilage tissue when implanted into athymic mice.  There are several possible 
reasons to explain these results as well as alternative approaches that could improve 
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chondrogenesis in the microbead system.  The RCs demonstrated they were capable of 
forming cartilage nodules at the implantation site when not suspended in alginate.  This 
suggests the lack of chondrogenesis is the result of the alginate restricting cell 
proliferation and matrix synthesis.  This hypothesis could be tested by modifying the 
microbead system to degrade faster.  Possible methods to achieve this include using a 
lower concentration of alginate, gamma irradiating the alginate to reduce the molecular 
weight, and mixing in other substances into the alginate like gelatin that will degrade 
more rapidly.   
Reducing the total amount of alginate by increasing the cell density would also 
decrease the degradation time.  In addition, our results and previous studies have shown 
that cell seeding density is important in regulating the phenotype of chondrocytes 67, 238.  
It is unknown why chondrocytes require a high cell density to maintain a differentiated 
state.  One possible explanation is that a critical threshold of autocrine or paracrine 
factors must be produced locally by the chondrocytes.  It is known chondrocytes are 
capable of producing several factors locally, including steroid hormones like estrogen.  
Cell-matrix interactions are also very important for maintaining a chondrocytic 
phenotype.  A greater number of chondrocytes would produce more extracellular matrix 
and therefore facilitate these interactions.  Lastly, chondrocytes may also require cell-cell 
interactions similar to osteocytes.  These cell-cell connections could provide another 
avenue for information to pass between cells via receptor mediated pathways or 
junctions. 
Our choice of implantation site also could have influenced the ability of the 
microbeads to form cartilaginous tissue.  As previously discussed, cartilage is an 
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avascular tissue and therefore the normal physiologic environment is poor in oxygen and 
serum components.  The intramuscular implant site was chosen because induced 
endochondral ossification by demineralized bone matrix (DBM) has been shown to be 
optimal in this location.  A different implant site, however, may be preferable for forming 
cartilage with our microbead system.  The most obvious choice is to use a cartilage defect 
model.  This has the advantage of mimicking the eventual clinical scenario, but a 
cartilage site also has several disadvantages as well.  The size of the implant is restricted 
by the joint which can be significantly limiting in the case of rodents.  In addition, 
articular sites introduce mechanical forces which can dislodge and damage the implant, 
as well as provide an uncontrolled variable to the system.  Non-load bearing sites like the 
xiphoid could be used to circumvent this issue.  Another commonly used implant site is 
the skin.  A subcutaneous pouch is more nutrient poor compared to muscle and alginate 
constructs have been shown to be form cartilage-like tissue in such models 238. 
The minimal degradation we observed in our system could have also been the 
result of the animal model chosen.  The athymic mice have an impaired immune system 
which is beneficial for the implanted xenogeneic cells, but this could have reduced the 
enzymatic degradation of the alginate 238.  This problem could potentially be 
circumvented by using allogeneic cells of inbred rodent strains, thereby eliminating the 
need for athymic animals.  However, the use of allogeneic mature chondrocytes would 
still require the expansion of cells over multiple passages to provide a sufficient cell 
number capable of repairing a cartilage defect.  As previously discussed, monolayer 
expansion negatively impacts the phenotype of chondrocytes.  One possible solution 
would be to use adult stem cells derived from mesenchymal tissues including bone 
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marrow stroma, muscle, and fat.  Mesenchymal stem cells (MSCs) have the benefit of 
being able to divide indefinitely allowing substantial expansion of the cell source.  The 
MSCs could then be differentiated towards a chondrogenic phenotype using various 
growth factor protocols previously discussed.  Moreover, the use three dimensional 
suspension culture has been shown to enhance the differentiation of MSCs towards a 
chondrogenic phenotype. 
The microbead technology has other possible applications in tissue engineering 
besides the use as a culture system.  The microbeads also provide the potential for double 
encapsulation procedures.  The small size of the microbeads would allow them to be 
suspended in a second alginate and cell solution.  This solution could then be extruded 
through a larger bore needle to form constructs with islands of microbeads.  Different 
combinations of cells could be used to form heterogeneous tissue arrangements.  
Examples include the mixture of mature osteoblasts or chondrocytes with mesenchymal 
stem cells, or the use of microbeads with vascular progenitor cells to form vascularized 
tissues like bone, liver, or spleen.  Microbeads with cells genetically engineered to 
express specific growth factors could also be used in this system to provide a more 
uniform gradient compared to diffusion of factors from the bulk fluid. 
Finally, further investigation between the interaction of hormones and hydrogel 
suspension should be investigated.  As previous mentioned, E2 and alginate encapsulation 
have been shown to activate the same protein kinase C (PKC) isoform.  It is unknown 
whether this could result in a synergistic increase in chondrogenesis, or have a negative 
effect due to over-stimulation.  Moreover, it has been shown that estrogen treatment can 
increase SOX-9 expression in chondrocytes.  This study and others have shown alginate 
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suspension increases SOX-9 expression, further supporting a possible interaction.  A 
thorough understanding of the complex interactions between cells, scaffolds and 
environment is needed before a successful strategy for cartilage tissue engineering and 
regeneration can be developed. 
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